Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study.
paper
Cited
Public
Unavailable
- Authors
- Anthonisen, N R; Connett, J E; Kiley, J P; Altose, M D; Bailey, W C; Buist, A S; Conway, W A; Enright, P L; Kanner, R E; O'Hara, P
- Year
- 1994
- Journal
- JAMA
- PMID
- 7966841
OBJECTIVE: To determine whether a program incorporating smoking intervention and use of an inhaled bronchodilator can slow the rate of decline in forced expiratory volume in 1 second (FEV1) in smokers aged 35 to 60 years who have mild obstructive pulmonary disease. DESIGN: Randomized clinical trial. Participants randomized with equal probability to one of the following groups: (1) smoking intervention plus bronchodilator, (2) smoking intervention plus placebo, or (3) no intervention. SETTING: Ten clinical centers in the United States and Canada. PARTICIPANTS: A total of 5887 male and female smokers, aged 35 to 60 years, with spirometric signs of early chronic obstructive pulmonary disease. INTERVENTIONS: Smoking intervention: intensive 12-session smoking cessation program combining behavior modification and use of nicotine gum, with continuing 5-year maintenance program to minimize relapse. Bronchodilator: ipratropium bromide prescribed three times daily (two puffs per time) from a metered-dose inhaler. MAIN OUTCOME MEASURES: Rate of change and cumulative change in FEV1 over a 5-year period. RESULTS: Participants in the two smoking intervention groups showed significantly smaller declines in FEV1 than did those in the control group. Most of this difference occurred during the first year following entry into the study and was attributable to smoking cessation, with those who achieved sustained smoking cessation experiencing the largest benefit. The small noncumulative benefit associated with use of the active bronchodilator vanished after the bronchodilator was discontinued at the end of the study. CONCLUSIONS: An aggressive smoking intervention program significantly reduces the age-related decline in FEV1 in middle-aged smokers with mild airways obstruction. Use of an inhaled anticholinergic bronchodilator results in a relatively small improvement in FEV1 that appears to be reversed after the drug is discontinued. Use of the bronchodilator did not influence the long-term decline of FEV1.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Duration of Smoking Cessation Needed to Achieve Retear Rates Comparable to Those of Nonsmokers After Arthroscopic Rotator Cuff Repair. | Chang HH et al. | — | 2026 | → |
| Personalizing COPD care: Phenotypes, endotypes, GETomics, the trajectome, syndemics and treatable traits. | Agusti A et al. | — | 2026 | → |
| Plasma proteomic profiling with machine learning identifies immunometabolic perturbations associated with smoking and smoking cessation. | Ma J et al. | — | 2026 | → |
| The effects of a smoking cessation intervention on mortality after a 32.5-year follow-up period: a randomized clinical trial. | Zhang J et al. | — | 2026 | → |
| Airflow obstruction among young adults in Europe: a Chronic Airway Diseases Early Stratification (CADSET) collaboration with 48 612 individuals across eight population-based cohorts. | Çolak Y et al. | — | 2025 | → |
| Appraisal of β-Blocker Use in Patients with Cardiovascular Disease and Chronic Obstructive Pulmonary Disease. | Xue R et al. | — | 2025 | → |
| Association Between Serum Growth Factors and Risk of Acute Exacerbation in Chronic Obstructive Pulmonary Disease: A One-Year Prospective Study. | Tien HY et al. | — | 2025 | → |
| Current Smoker: A Clinical Chronic Obstructive Pulmonary Disease Phenotype Affecting Disease Progression and Response to Therapy. | Celli BR et al. | — | 2025 | → |
| Cyclodextrin-Based Nanotransporters as a Versatile Tool to Manage Oxidative Stress-Induced Lung Diseases. | Hallan SS et al. | — | 2025 | → |
| Impact of Smoking and Sociodemographic Factors on Self-Reported Chronic Obstructive Pulmonary Disease Among U.S. Adults: A Retrospective Study. | Bhat S et al. | — | 2025 | → |
| PIGEON: a statistical framework for estimating gene-environment interaction for polygenic traits. | Miao J et al. | — | 2025 | → |
| Relationship Between COPD Progression and Frailty Progression: A Five-year Observation in Real Clinical Practice. | Nishimura K et al. | — | 2025 | → |
| Short-Term and Long-Term Effects of Electronic Cigarettes on Mouse Lungs Following Nose-Only Exposures. | Sinha I et al. | — | 2025 | → |
| The Emerging Role of Alarmin-Targeting Biologics in the Treatment of Patients With COPD. | Celli BR et al. | — | 2025 | → |
| The global burden of COPD: epidemiology and effect of prevention strategies. | de Oca MM et al. | — | 2025 | → |
| The Saudi Thoracic Society Evidence-based guidelines for the diagnosis and management of chronic obstructive pulmonary disease. | Al-Jahdali H et al. | — | 2025 | → |
| The uphill journey of smoking cessation in chronic obstructive pulmonary disease: why a well-built vehicle matters. | Jakobsen RK et al. | — | 2025 | → |
| Uniportal Video-Assisted Anatomical Lung Volume Reduction Surgery in Severe Emphysema. | Merhej H et al. | — | 2025 | → |
| AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD. | Rabe KF et al. | — | 2024 | → |
| Demographic and Clinical Characteristics of Mild, Young and Early COPD: A Cross-Sectional Analysis of 5468 Patients. | Aljama C et al. | — | 2024 | → |
| Duration and Frequency of Spirometry Needed to Accurately Reflect Annualized Change of FEV<sub>1</sub> in Chronic Obstructive Pulmonary Disease. | Wilkinson JD et al. | — | 2024 | → |
| Effects of smoking cessation on individuals with COPD: a systematic review and meta-analysis. | Wang Z et al. | — | 2024 | → |
| Estimating rate of lung function change using clinical spirometry data. | Balasubramanian A et al. | — | 2024 | → |
| Low smoking exposure and development and prognosis of COPD over four decades: a population-based cohort study. | Çolak Y et al. | — | 2024 | → |
| Multidisciplinary Management of Patients With Chronic Obstructive Pulmonary Disease and Cardiovascular Disease. | de Miguel-Díez J et al. | — | 2024 | → |
| Susceptible Young Adults and Development of Chronic Obstructive Pulmonary Disease Later in Life. | Çolak Y et al. | — | 2024 | → |
| The association between long-acting muscarinic antagonist-based therapy and the risk of urinary tract infection in patients with chronic obstructive pulmonary disease. | Li P et al. | — | 2024 | → |
| The memory of airway epithelium damage in smokers and COPD patients. | Carlier FM et al. | — | 2024 | → |
| Analyzing clustered continuous response variables with ordinal regression models. | Tian Y et al. | — | 2023 | → |
| Association of cigarette smoking with increased use of heated tobacco products in middle-aged and older adults with self-reported chronic obstructive pulmonary disease, asthma, and asthma-COPD overlap in Japan, 2022: the JASTIS study. | Noguchi S et al. | — | 2023 | → |
| COPD: Providing the right treatment for the right patient at the right time. | Agusti A et al. | — | 2023 | → |
| CT Imaging With Machine Learning for Predicting Progression to COPD in Individuals at Risk. | Makimoto K et al. | — | 2023 | → |
| Extracellular Vesicle-Encapsulated microRNAs as Novel Biomarkers of Lung Health. | Eckhardt CM et al. | — | 2023 | → |
| Faster lung function decline in people living with HIV despite adequate treatment: a longitudinal matched cohort study. | Thudium RF et al. | — | 2023 | → |
| Frailty Index is Associated with Treatment Decisions for Stage I Non-Small Cell Lung Cancer at a High-Burden Safety-Net Hospital. | Asokan S et al. | — | 2023 | → |
| From pre-COPD to COPD: a Simple, Low cost and easy to IMplement (SLIM) risk calculator. | Divo MJ et al. | — | 2023 | → |
| Smoking cessation after diagnosis of COPD is associated with lower all-cause and cause-specific mortality: a nationwide population-based cohort study of South Korean men. | Doo JH et al. | — | 2023 | → |
| [Smoking cessation in hospitalised patients - Initiate among inpatients, continue when outpatients - A Position Paper by the German Respiratory Society (DGP) Taskforce for Smoking Cessation]. | Raspe M et al. | — | 2023 | → |
| Smoking Cessation Interventions for Patients With Chronic Obstructive Pulmonary Disease: A NARRATIVE REVIEW WITH IMPLICATIONS FOR PULMONARY REHABILITATION. | Coleman SRM et al. | — | 2023 | → |
| The Importance of Early Chronic Obstructive Pulmonary Disease: A Lecture from 2022 Asian Pacific Society of Respirology. | Sin DD | — | 2023 | → |
| Unmet Diagnostic and Therapeutic Opportunities for Chronic Obstructive Pulmonary Disease in Low- and Middle-Income Countries. | Florman KEH et al. | — | 2023 | → |
| Analysis of pathogenesis and drug treatment of chronic obstructive pulmonary disease complicated with cardiovascular disease. | Li XF et al. | — | 2022 | → |
| Association between annual change in FEV<sub>1</sub> and comorbidities or impulse oscillometry in chronic obstructive pulmonary disease. | Sugawara H et al. | — | 2022 | → |
| Characteristics of patients referred to Canary Island pneumology outpatient services for chronic obstructive pulmonary disease: the EPOCan study. | Figueira-Gonçalves JM et al. | — | 2022 | → |
| Decreased humoral immune response in the bronchi of rapid decliners with chronic obstructive pulmonary disease. | Di Stefano A et al. | — | 2022 | → |
| Developments in smoking cessation interventions for patients with chronic obstructive pulmonary disease in the past 5 years: a scoping review. | Feng L et al. | — | 2022 | → |
| Do deaths from competing risks influence COPD patterns in China and high socio-demographic index countries?: a cross-sectional analysis of summary statistics from the Global Burden of Disease Study 2017. | Yang Z et al. | — | 2022 | → |
| Educational interventions for health professionals managing chronic obstructive pulmonary disease in primary care. | Cross AJ et al. | — | 2022 | → |
| Effect of Smoking and Its Cessation on the Transcript Profile of Peripheral Monocytes in COPD Patients. | Trivedi A et al. | — | 2022 | → |
| Effect of Smoking on Lung Function Decline in a Retrospective Study of a Health Examination Population in Chinese Males. | Tian T et al. | — | 2022 | → |
| Extended Investigation of Exposure to Respirable Synthetic Amorphous Silica Dust and Its Potential Impact on Non-malignant Respiratory Morbidity. | Yong M et al. | — | 2022 | → |
| [French clinical practice guidelines for the diagnosis and management of lung disease with alpha 1-antitrypsin deficiency]. | Mornex JF et al. | — | 2022 | → |
| Health impact of e-cigarettes and heated tobacco products in chronic obstructive pulmonary disease: current and emerging evidence. | Morjaria JB et al. | — | 2022 | → |
| Intensive <i>versus</i> short face-to-face smoking cessation interventions: a meta-analysis. | Rasmussen M et al. | — | 2022 | → |
| New Perspectives on Chronic Obstructive Pulmonary Disease. | Celli BR et al. | — | 2022 | → |
| NHLBI ASTHMA NETWORKS: IMPROVING PATIENT CARE, MOVING TOWARD PERSONALIZED MEDICINE. | Peters SP | — | 2022 | → |
| Pharmacological smoking cessation of adults aged 30-50 years with COPD. | Andelius DK et al. | — | 2022 | → |
| Prevalence, characteristics, and risk of exacerbation in young patients with chronic obstructive pulmonary disease. | Jo YS et al. | — | 2022 | → |
| Race and Sex Differences in Mortality in Individuals with Chronic Obstructive Pulmonary Disease. | Krishnan JK et al. | — | 2022 | → |
| Reversal of NADPH Oxidase-Dependent Early Oxidative and Inflammatory Responses in Chronic Obstructive Pulmonary Disease by Puerarin. | Zhang P et al. | — | 2022 | → |
| Reversible Airflow Obstruction Predicts Future Chronic Obstructive Pulmonary Disease Development in the SPIROMICS Cohort: An Observational Cohort Study. | Buhr RG et al. | — | 2022 | → |
| Screening for preclinical parenchymal lung disease in rheumatoid arthritis. | Esposito AJ et al. | — | 2022 | → |
| Treatable Traits in Misdiagnosed Chronic Obstructive Pulmonary Disease: Data from the Akershus Cardiac Examination 1950 Study. | Caspersen NF et al. | — | 2022 | → |
| Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. | Martinez FJ et al. | — | 2022 | → |
| Varenicline for Gradual Versus Abrupt Smoking Cessation in Poorly Motivated Smokers With COPD: A Prematurely Terminated Randomized Controlled Trial. | Bohadana A et al. | — | 2022 | → |
| Why small particle fixed dose triple therapy? An excursus from COPD pathology to pharmacological treatment evolution. | Braido F et al. | — | 2022 | → |
| ACO (Asthma-COPD Overlap) Is Independent from COPD: The Case in Favour. | Calverley PMA et al. | — | 2021 | → |
| A few more steps lead to improvements in endothelial function in severe and very severe COPD. | Kohlbrenner D et al. | — | 2021 | → |
| Association between smoking cessation and obstructive spirometry pattern among Korean adults aged 40-79 years. | Yoon YJ et al. | — | 2021 | → |
| Clinical Audit on Chronic Obstructive Pulmonary Disease (COPD) Management in Primary Care: A Quality Improvement Project from Hong Kong. | Chen XRC et al. | — | 2021 | → |
| COPD and Cardiovascular Disease: A Review of Association, Interrelationship, and Basic Principles for Integrated Management. | Shnoda M et al. | — | 2021 | → |
| Dynamic Metabolic Risk Profiling of World Trade Center Lung Disease: A Longitudinal Cohort Study. | Kwon S et al. | — | 2021 | → |
| Early chronic obstructive pulmonary disease: A new perspective. | Lu HH et al. | — | 2021 | → |
| Gallic acid ameliorates COPD-associated exacerbation in mice. | Singla E et al. | — | 2021 | → |
| Health outcomes in COPD smokers using heated tobacco products: a 3-year follow-up. | Polosa R et al. | — | 2021 | → |
| Impact of a Medical Diagnosis on Decision to Stop Smoking and Successful Smoking Cessation. | Lindsay HG et al. | — | 2021 | → |
| Impaired Respiratory Health and Life Course Transitions From Health to Chronic Lung Disease. | Liu GY et al. | — | 2021 | → |
| Mild catalytic defects of tert rs61748181 polymorphism affect the clinical presentation of chronic obstructive pulmonary disease. | Xu J et al. | — | 2021 | → |
| More to Explore: Further Definition of Risk Factors for COPD - Differential Gender Difference, Modest Elevation in PM<sub>2</sub>.<sub>5</sub>, and e-Cigarette Use. | Zhang Y et al. | — | 2021 | → |
| Natural history and mechanisms of COPD. | Lange P et al. | — | 2021 | → |
| Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review. | Celli BR et al. | — | 2021 | → |
| Rate of Decline of FEV<sub>1</sub> as a Biomarker of Survival? | Papi A et al. | — | 2021 | → |
| Serum Concentration of the Phytohormone Abscisic Acid Is Associated With Immune-Regulatory Mediators and Is a Potential Biomarker of Disease Severity in Chronic Obstructive Pulmonary Disease. | Hoang QTM et al. | — | 2021 | → |
| Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis. | Thomas KH et al. | — | 2021 | → |
| The Efficacy and Safety of Revefenacin for the Treatment of Chronic Obstructive Pulmonary Disease: A Systematic Review. | Zhang J et al. | — | 2021 | → |
| The memory of airway epithelium damage in smokers and COPD patients | Carlier FM et al. | — | 2021 | — |
| Tobacco use disorder and the lungs. | McRobbie H et al. | — | 2021 | → |
| Treatable traits in an English cohort: prevalence and predictors of future decline in lung function and quality of life in COPD. | Sarwar MR et al. | — | 2021 | → |
| Bu-Shen-Fang-Chuan formula attenuates T-lymphocytes recruitment in the lung of rats with COPD through suppressing CXCL9/CXCL10/CXCL11-CXCR3 axis. | Li Q et al. | — | 2020 | → |
| Chronic obstructive pulmonary disease and related phenotypes: polygenic risk scores in population-based and case-control cohorts. | Moll M et al. | — | 2020 | → |
| Cigarette smoking and lung function decline beyond quitting. | Perret JL et al. | — | 2020 | → |
| COPD smokers who switched to e-cigarettes: health outcomes at 5-year follow up. | Polosa R et al. | — | 2020 | → |
| Diagnosis and Treatment of Early Chronic Obstructive Lung Disease (COPD). | Choi JY et al. | — | 2020 | → |
| Does gallic acid improve cardiac function by attenuation of oxidative stress and inflammation in an elastase-induced lung injury? | Sohrabi F et al. | — | 2020 | → |
| Early COPD: current evidence for diagnosis and management. | Fazleen A et al. | — | 2020 | → |
| Effect of Early Initiation of Varenicline on Smoking Cessation in COPD Patients Admitted for Exacerbation: The Save Randomized Clinical Trial. | Le Mao R et al. | — | 2020 | → |
| Efficacy and safety of Jia Wei Bushen Yiqi formulas as an adjunct therapy to systemic glucocorticoids on acute exacerbation of COPD: study protocol for a randomized, double-blinded, multi-center, placebo-controlled clinical trial. | Kong Q et al. | — | 2020 | → |
| Integrating Comorbidities and Phenotype-Based Medicine in Patient-Centered Medicine in COPD. | Lopez-Campos JL et al. | — | 2020 | → |
| Lung function decline in former smokers and low-intensity current smokers: a secondary data analysis of the NHLBI Pooled Cohorts Study. | Oelsner EC et al. | — | 2020 | → |
| Observational studies assessing the pharmacological treatment of obstructive lung disease: strengths, challenges and considerations for study design. | Vestbo J et al. | — | 2020 | → |
| Outcomes and predictive factors for successful smoking cessation therapy in COPD patients with nicotine dependence. | Hashimoto R et al. | — | 2020 | → |
| Outcome weighted <i>ψ</i>-learning for individualized treatment rules. | Liu M et al. | — | 2020 | → |
| Poor initiation of smoking cessation therapies in hospitalised patients with chronic obstructive pulmonary disease is associated with low levels of formal training among hospital doctors and under-utilisation of nursing-led interventions. | Pham J et al. | — | 2020 | → |
| Prevalence, Characteristics, and Prognosis of Early Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. | Çolak Y et al. | — | 2020 | → |
| Pulmonary Function Changes in Chronic Obstructive Pulmonary Disease Patients According to Smoking Status. | Gülşen A | — | 2020 | → |
| Smoking Cessation/Vaccinations. | Montes de Oca M | — | 2020 | → |
| Smoking, DNA Methylation, and Lung Function: a Mendelian Randomization Analysis to Investigate Causal Pathways. | Jamieson E et al. | — | 2020 | → |
| Two-Phase, Generalized Case-Control Designs for the Study of Quantitative Longitudinal Outcomes. | Schildcrout JS et al. | — | 2020 | → |
| A Genetic Risk Score Associated with Chronic Obstructive Pulmonary Disease Susceptibility and Lung Structure on Computed Tomography. | Oelsner EC et al. | — | 2019 | → |
| A Narrative Review of Intensive Group Tobacco Treatment: Clinical, Research, and US Policy Recommendations. | Kotsen C et al. | — | 2019 | → |
| Annual change in FEV<sub>1</sub> in elderly 10-year survivors with established chronic obstructive pulmonary disease. | Suzuki M et al. | — | 2019 | → |
| Biomedical risk assessment as an aid for smoking cessation. | Clair C et al. | — | 2019 | → |
| Celebration of the 50-Year Anniversary of the National Heart, Lung, and Blood Institute Division of Lung Diseases: A Half-Century of Landmark Clinical Trials. | Wise RA et al. | — | 2019 | → |
| COPD and Cardiovascular Disease. | André S et al. | — | 2019 | → |
| Effects of cardiopulmonary bypass on pulmonary function in COPD patients undergoing beating heart coronary artery bypass surgery. | Çetin E et al. | — | 2019 | → |
| Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT. | D'Urzo AD et al. | — | 2019 | → |
| Fifty Years of Progress in the Epidemiology of Chronic Obstructive Pulmonary Disease: A Review of National Heart, Lung, and Blood Institute-Sponsored Studies. | Mannino DM | — | 2019 | → |
| Imidafenacin, An Orally Active Muscarinic Receptor Antagonist, Improves Pulmonary Function In Patients With Chronic Obstructive Pulmonary Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled 3×3 Crossover Phase II Trial. | Machida K et al. | — | 2019 | → |
| Indoor particulate matter and lung function in children. | Isiugo K et al. | — | 2019 | → |
| Inhaled corticosteroids and the risk of lung cancer in COPD: a population-based cohort study. | Raymakers AJN et al. | — | 2019 | → |
| Initiating drug therapy in early stage chronic obstructive pulmonary disease: does it impact the course and outcome? | Burkes RM et al. | — | 2019 | → |
| Innovating the treatment of COPD exacerbations: a phone interactive telesystem to increase COPD Action Plan adherence. | Farias R et al. | — | 2019 | → |
| Longitudinal airway remodeling in active and past smokers in a lung cancer screening population. | Jobst BJ et al. | — | 2019 | → |
| Longitudinal decline in lung function: a community-based cohort study in Korea. | Leem AY et al. | — | 2019 | → |
| Losartan does not inhibit cigarette smoke-induced lung inflammation in mice. | Hepworth ML et al. | — | 2019 | → |
| Mediation analysis for common binary outcomes. | Gaynor SM et al. | — | 2019 | → |
| Model-based evaluation of the long-term cost-effectiveness of systematic case-finding for COPD in primary care. | Lambe T et al. | — | 2019 | → |
| New frontiers in the treatment of comorbid cardiovascular disease in chronic obstructive pulmonary disease. | Brassington K et al. | — | 2019 | → |
| Pharmacogenomics of chronic obstructive pulmonary disease. | Hersh CP | — | 2019 | → |
| Predicting Indoor Concentrations of Black Carbon in Residential Environments. | Isiugo K et al. | — | 2019 | → |
| Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study. | Contoli M et al. | — | 2019 | → |
| Spirometric indices of early airflow impairment in individuals at risk of developing COPD: Spirometry beyond FEV<sub>1</sub>/FVC. | Hoesterey D et al. | — | 2019 | → |
| The etiologic origins for chronic obstructive pulmonary disease. | Huang X et al. | — | 2019 | → |
| The Impact of a Newly Established Multidisciplinary Team on the Interventional Treatment of Patients With Emphysema. | Kouritas V et al. | — | 2019 | → |
| Tiotropium discontinuation in patients with early-stage COPD: a prospective observational cohort study. | Li C et al. | — | 2019 | → |
| Using a Health Economic Framework to Prioritize Quality Indicators: An Example With Smoking Cessation in Chronic Obstructive Pulmonary Disease. | Nam A et al. | — | 2019 | → |
| Aging-related trajectories of lung function in the general population-The Doetinchem Cohort Study. | van Oostrom SH et al. | — | 2018 | → |
| Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications. | Chapman KR et al. | — | 2018 | → |
| An Epidemiological Study of Population Health Reveals Social Smoking as a Major Cardiovascular Risk Factor. | Gawlik KS et al. | — | 2018 | → |
| Anti-inflammatory effects of embelin in A549 cells and human asthmatic airway epithelial tissues. | Lee IS et al. | — | 2018 | → |
| At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. | Martinez FJ et al. | — | 2018 | → |
| Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota. | Morgillo F et al. | — | 2018 | → |
| COPD in China: From Crisis to Hope…. | Yoon HI et al. | — | 2018 | → |
| COPD in patients after heart transplantation is associated with a prolonged hospital stay, early posttransplant atrial fibrillation, and impaired posttransplant survival. | Rivinius R et al. | — | 2018 | → |
| Defining the relationship between COPD and CVD: what are the implications for clinical practice? | Morgan AD et al. | — | 2018 | → |
| Disease Management plus Recommended Care versus Recommended Care Alone for Ambulatory Patients with Chronic Obstructive Pulmonary Disease. | Kalter-Leibovici O et al. | — | 2018 | → |
| Effect of Aerobic Exercises on Serum Levels of Apolipoprotein A1 and Apolipoprotein B, and Their Ratio in Patients with Chronic Obstructive Pulmonary Disease. | Yazdani R et al. | — | 2018 | → |
| Effects of Systematic Intervention for Chronic Obstructive Pulmonary Disease on Follow-up and Smoking Cessation Rates and Changes of the Pulmonary Function: A 7-year Longitudinal Study in a Japanese Rural City. | Tanaka K et al. | — | 2018 | → |
| Electronic cigarettes: an aid in smoking cessation, or a new health hazard? | Farsalinos K | — | 2018 | → |
| Environmental exposures and systemic hypertension are risk factors for decline in lung function. | Miele CH et al. | — | 2018 | → |
| Exacerbations of COPD. | Viniol C et al. | — | 2018 | → |
| Extending the Case-Control Design to Longitudinal Data: Stratified Sampling Based on Repeated Binary Outcomes. | Schildcrout JS et al. | — | 2018 | → |
| Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. | Calverley PMA et al. | — | 2018 | → |
| Health effects in COPD smokers who switch to electronic cigarettes: a retrospective-prospective 3-year follow-up. | Polosa R et al. | — | 2018 | → |
| Hydrogen gas inhalation protects against cigarette smoke-induced COPD development in mice. | Lu W et al. | — | 2018 | → |
| Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy? | Tashkin DP et al. | — | 2018 | → |
| Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the Spanish registry (REDAAT). | Esquinas C et al. | — | 2018 | → |
| Lung Dysfunction and Mortality in Patients with Chronic Kidney Disease. | Mukai H et al. | — | 2018 | → |
| Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease. | Sliwka A et al. | — | 2018 | → |
| Pharmacological Therapy of COPD: Reasons for Optimism. | Celli BR | — | 2018 | → |
| Predictors of Continued Smoking and Interest in Cessation Among Older Female Smokers. | Weaver KE et al. | — | 2018 | → |
| Predictors of COPD in symptomatic smokers and ex-smokers seen in primary care. | Tupper OD et al. | — | 2018 | → |
| Prevention and Treatment of Tobacco Use: JACC Health Promotion Series. | Kalkhoran S et al. | — | 2018 | → |
| Reaching for the Holy Grail of Chronic Obstructive Pulmonary Disease Outcomes. Can Medications Modify Lung Function Decline? | Aaron SD | — | 2018 | → |
| Reprint of: Prevention and Treatment of Tobacco Use: JACC Health Promotion Series. | Kalkhoran S et al. | — | 2018 | → |
| Review of biomarkers to assess the effects of switching from cigarettes to modified risk tobacco products. | Peck MJ et al. | — | 2018 | → |
| Revised (2018) COPD Clinical Practice Guideline of the Korean Academy of Tuberculosis and Respiratory Disease: A Summary. | Park YB et al. | — | 2018 | → |
| Self management of patients with mild COPD in primary care: randomised controlled trial. | Jolly K et al. | — | 2018 | → |
| Smoking and Accelerated Lung Function Decline in HIV-Positive Individuals: A Secondary Analysis of the START Pulmonary Substudy. | MacDonald DM et al. | — | 2018 | → |
| Smoking-Cessation Efforts by US Adult Smokers with Medical Comorbidities. | Kalkhoran S et al. | — | 2018 | → |
| Smoking In COPD Patients: A New Clinical Phenotype? | Carrión Valero F et al. | — | 2018 | → |
| Socioeconomic disparities and chronic respiratory diseases in Thailand: The National Socioeconomics Survey. | Luenam A et al. | — | 2018 | → |
| Systematic review of inhaled corticosteroid withdrawal effects in chronic obstructive pulmonary disease, and comparison with two "real-life" studies. | Ye W et al. | — | 2018 | → |
| The genetics of smoking in individuals with chronic obstructive pulmonary disease. | Obeidat M et al. | — | 2018 | → |
| Web-based Health Information Seeking and eHealth Literacy among Patients Living with Chronic Obstructive Pulmonary Disease (COPD). | Stellefson ML et al. | — | 2018 | → |
| What is early COPD and why is it important? | Soriano JB et al. | — | 2018 | → |
| Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease. | Dransfield MT et al. | — | 2017 | → |
| Case-Control Study: Smoking History Affects the Production of Tumor Antigen-Specific Antibodies NY-ESO-1 in Patients with Lung Cancer in Comparison with Cancer Disease-Free Group. | Myšíková D et al. | — | 2017 | → |
| Chronic Obstructive Pulmonary Disease. | O'Reilly S | — | 2017 | → |
| Chronic obstructive pulmonary disease with mild airflow limitation: current knowledge and proposal for future research - a consensus document from six scientific societies. | Rossi A et al. | — | 2017 | → |
| Completion rates in a preoperative surgical weight loss program by tobacco use status. | Veldheer S et al. | — | 2017 | → |
| COPD-Therapie in Praxis und Spital: Exazerbationen verhindern, Prognose verbessern. | Barandun J | — | 2017 | → |
| Development and validation of the Salzburg COPD-screening questionnaire (SCSQ): a questionnaire development and validation study. | Weiss G et al. | — | 2017 | → |
| Diagnostic Instability and Reversals of Chronic Obstructive Pulmonary Disease Diagnosis in Individuals with Mild to Moderate Airflow Obstruction. | Aaron SD et al. | — | 2017 | → |
| Donor Smoking and Older Age Increases Morbidity and Mortality After Lung Transplantation. | Schultz HH et al. | — | 2017 | → |
| E-cigarettes in patients with COPD: current perspectives. | Morjaria JB et al. | — | 2017 | → |
| Effectiveness of intensive smoking reduction counselling plus combination nicotine replacement therapy in promoting long-term abstinence in patients with chronic obstructive pulmonary disease not ready to quit smoking: Protocol of the REDUQ trial. | Hagens P et al. | — | 2017 | → |
| Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD. | Monaco TJ et al. | — | 2017 | → |
| Endothelial progenitor cell dysfunction in acute exacerbation of chronic obstructive pulmonary disease. | Liu X et al. | — | 2017 | → |
| Factors associated with pulmonary impairment in HIV-infected South African adults. | Gupte AN et al. | — | 2017 | → |
| Fletcher and Peto 40 Years On. A Tribute and Reflection. | Vestbo J et al. | — | 2017 | → |
| Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. | Vogelmeier CF et al. | — | 2017 | → |
| Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. | Vogelmeier CF et al. | — | 2017 | → |
| Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. | Vogelmeier CF et al. | — | 2017 | → |
| Incidence of cancer in outpatients with chronic obstructive pulmonary disease. | Figueira Gonçalves JM et al. | — | 2017 | → |
| Inhaled Long-acting Anticholinergics and Urinary Tract Infection in Individuals with COPD. | Gershon AS et al. | — | 2017 | → |
| Is Cost of Medication for Quit Smoking Important for Smokers, Experience of Using Champix in Iranian Smoking Cessation Program 2016. | Heydari G | — | 2017 | → |
| Longitudinal changes in structural abnormalities using MDCT in COPD: do the CT measurements of airway wall thickness and small pulmonary vessels change in parallel with emphysematous progression? | Takayanagi S et al. | — | 2017 | → |
| Long-term effects of beta-blocker use on lung function in Japanese patients with chronic obstructive pulmonary disease. | Oda N et al. | — | 2017 | → |
| Long-Term Oxygen for COPD. | Eliasson O | — | 2017 | → |
| Long time enzyme replacement therapy stabilizes obstructive lung disease and alters peripheral immune cell subsets in Fabry patients. | Odler B et al. | — | 2017 | → |
| Peripheral leukocyte microRNAs as novel biomarkers for COPD. | Wang R et al. | — | 2017 | → |
| Pharmacological Management of People Living with End-Stage Chronic Obstructive Pulmonary Disease. | Dalgliesh V et al. | — | 2017 | → |
| Prevalence and risk factors of airflow limitation in a Mongolian population in Ulaanbaatar: Cross-sectional studies. | Nakao M et al. | — | 2017 | → |
| Responsiveness to Ipratropium Bromide in Male and Female Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease. | Li X et al. | — | 2017 | → |
| Role and regulation of MKP-1 in airway inflammation. | Moosavi SM et al. | — | 2017 | → |
| [Should treatment of chronic obstructive pulmonary disease be based on multidimensional scales?] | Figueira-Gonçalves JM et al. | — | 2017 | → |
| Summary of the Chronic Obstructive Pulmonary Disease Clinical Practice Guideline Revised in 2014 by the Korean Academy of Tuberculosis and Respiratory Disease. | Yoon HK et al. | — | 2017 | → |
| Surfactant protein D is a causal risk factor for COPD: results of Mendelian randomisation. | Obeidat M et al. | — | 2017 | → |
| The important role of primary care providers in the detection of alpha-1 antitrypsin deficiency. | Lascano JE et al. | — | 2017 | → |
| The potential role of endothelial dysfunction and platelet activation in the development of thrombotic risk in COPD patients. | Malerba M et al. | — | 2017 | → |
| A cohort study of the acute and chronic respiratory effects of toner exposure among handlers: a longitudinal analyses from 2004 to 2013. | Ikegami K et al. | — | 2016 | → |
| Age-related annual decline of lung function in patients with COPD. | Kim SJ et al. | — | 2016 | → |
| Airway hyperresponsiveness in chronic obstructive pulmonary disease: A marker of asthma-chronic obstructive pulmonary disease overlap syndrome? | Tkacova R et al. | — | 2016 | → |
| Airway remodelling in COPD: It's not asthma! | Jones RL et al. | — | 2016 | → |
| A Meta-Analysis of the Association of Chronic Obstructive Pulmonary Disease with Abdominal Aortic Aneurysm Presence. | Takagi H et al. | — | 2016 | → |
| Are COPD and cardiovascular disease fundamentally intertwined? | Bafadhel M et al. | — | 2016 | → |
| Cardiac effects of current treatments of chronic obstructive pulmonary disease. | Lahousse L et al. | — | 2016 | → |
| Comparative Cardiovascular and Cerebrovascular Safety of Inhaled Long-Acting Bronchodilators in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study. | Dong YH et al. | — | 2016 | → |
| Contribution of air pollution to COPD and small airway dysfunction. | Berend N | — | 2016 | → |
| COPD and squamous cell lung cancer: aberrant inflammation and immunity is the common link. | Bozinovski S et al. | — | 2016 | → |
| Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. | Singh D et al. | — | 2016 | → |
| Early intervention for chronic obstructive pulmonary disease by practice nurse and GP teams: a cluster randomized trial. | Zwar NA et al. | — | 2016 | → |
| Economic evaluation of a telephone- and face-to-face-delivered counseling intervention for smoking cessation in patients with coronary heart disease. | Berndt N et al. | — | 2016 | → |
| Economic evaluations of fluticasone-propionate/salmeterol combination therapy for chronic obstructive pulmonary disease: a review of published studies. | Roberts MH et al. | — | 2016 | → |
| Epidemiology of Lung Cancer. | Schwartz AG et al. | — | 2016 | → |
| Evidence for harm reduction in COPD smokers who switch to electronic cigarettes. | Polosa R et al. | — | 2016 | → |
| Exploring Issues of Comorbid Conditions in People Who Smoke. | Rojewski AM et al. | — | 2016 | → |
| Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management? | Stockley RA et al. | — | 2016 | → |
| Individualized prediction of lung-function decline in chronic obstructive pulmonary disease. | Zafari Z et al. | — | 2016 | → |
| Inflammatory bowel diseases, chronic liver diseases and the lung. | Rodriguez-Roisin R et al. | — | 2016 | → |
| Meeting the challenge of COPD care delivery in the USA: a multiprovider perspective. | Han MK et al. | — | 2016 | → |
| Natural history of COPD: Focusing on change in FEV1. | Vestbo J et al. | — | 2016 | → |
| No association of chronic obstructive pulmonary disease with abdominal aortic aneurysm growth. | Takagi H et al. | — | 2016 | → |
| Predictors of Pharmacotherapy for Tobacco Use Among Veterans Admitted for COPD: The Role of Disparities and Tobacco Control Processes. | Melzer AC et al. | — | 2016 | → |
| Prevalence of undiagnosed airflow obstruction among people with a history of smoking in a primary care setting. | Fu SN et al. | — | 2016 | → |
| Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial. | Kunisaki KM et al. | — | 2016 | → |
| Quantitative CT measurements of small pulmonary vessels in chronic obstructive pulmonary disease: do they change on follow-up scans? | Saruya S et al. | — | 2016 | → |
| Respiratory and Bronchitic Symptoms Predict Intention to Quit Smoking among Current Smokers with, and at Risk for, Chronic Obstructive Pulmonary Disease. | Melzer AC et al. | — | 2016 | → |
| Risk of Lung Cancer Associated with COPD Phenotype Based on Quantitative Image Analysis. | Schwartz AG et al. | — | 2016 | → |
| Smoking cessation for people with chronic obstructive pulmonary disease. | van Eerd EA et al. | — | 2016 | → |
| Strategies for Management of the Early Chronic Obstructive Lung Disease. | Lee JY et al. | — | 2016 | → |
| Unexpected improvements of lung function in chronic obstructive pulmonary disease. | Topalovic M et al. | — | 2016 | → |
| Use of cardioselective β-blockers and overall death and cardiovascular outcomes in patients with COPD: a population-based cohort study. | Dong YH et al. | — | 2016 | → |
| Use of varenicline for more than 12 months for smoking cessation in heavy chronic obstructive pulmonary disease smokers unmotivated to quit: a pilot study. | Sansores RH et al. | — | 2016 | → |
| Acetylcholine beyond bronchoconstriction: roles in inflammation and remodeling. | Kistemaker LE et al. | — | 2015 | → |
| A COPD health management program in a community-based primary care setting: a randomized controlled trial. | Lou P et al. | — | 2015 | → |
| A randomized controlled trial of vitamin E and selenium on rate of decline in lung function. | Cassano PA et al. | — | 2015 | → |
| [Are health district prevalence studies useful in family practice? Report of a case: chronic obstructive pulmonary disease]. | Casado Vicente V et al. | — | 2015 | → |
| Association of a disintegrin and metalloprotease 33 (ADAM33) gene polymorphisms with the risk of COPD: an updated meta-analysis of 2,644 cases and 4,804 controls. | Zhou DC et al. | — | 2015 | → |
| A systematic review of quality and cost-effectiveness derived from Markov models evaluating smoking cessation interventions in patients with chronic obstructive pulmonary disease. | Kirsch F | — | 2015 | → |
| Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends. | Montuschi P et al. | — | 2015 | → |
| Chronic obstructive pulmonary disease (COPD) assessment test scores corresponding to modified Medical Research Council grades among COPD patients. | Lee CH et al. | — | 2015 | → |
| Clinical and Immunological Factors in Emphysema Progression. Five-Year Prospective Longitudinal Exacerbation Study of Chronic Obstructive Pulmonary Disease (LES-COPD). | Bhavani S et al. | — | 2015 | → |
| COPD: early diagnosis and treatment to slow disease progression. | van der Molen T et al. | — | 2015 | → |
| COPD: early diagnosis and treatment to slow disease progression. | Welte T et al. | — | 2015 | → |
| Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines. | Kankaanranta H et al. | — | 2015 | → |
| Early chronic obstructive pulmonary disease: definition, assessment, and prevention. | Rennard SI et al. | — | 2015 | → |
| Effectiveness and safety of traditional Chinese medicine on stable chronic obstructive pulmonary disease: A systematic review and meta-analysis. | Haifeng W et al. | — | 2015 | → |
| Factors associated with the annual change in forced expiratory volume in 1 second of officially acknowledged victims of pollution-related illness in improved environments: a longitudinal study. | Yano Y et al. | — | 2015 | → |
| Implementation of a targeted screening program to detect airflow obstruction suggestive of chronic obstructive pulmonary disease within a presurgical screening clinic. | Robitaille C et al. | — | 2015 | → |
| Lung disease as a determinant of cognitive decline and dementia. | Dodd JW | — | 2015 | → |
| Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. | Lange P et al. | — | 2015 | → |
| Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. | Lee SJ et al. | — | 2015 | → |
| Mortality trends in women and men with COPD in Ontario, Canada, 1996-2012. | Gershon A et al. | — | 2015 | → |
| Nasal Mucociliary Clearance in Subjects With COPD After Smoking Cessation. | Ito JT et al. | — | 2015 | → |
| Non-pharmacological management of chronic obstructive pulmonary disease. | Safka KA et al. | — | 2015 | → |
| Optimizing Treatment of Elderly COPD Patients: What Role for Inhaled Corticosteroids? | Rossi AP et al. | — | 2015 | → |
| Prediction of 10-year risk of hard coronary events among Saudi adults based on prevalence of heart disease risk factors. | Soofi MA et al. | — | 2015 | → |
| Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. | Criner GJ et al. | — | 2015 | → |
| Self-reported symptoms of chronic cough and breathlessness in working-age men in the city of Izhevsk, Russia: associations with cardiovascular disease risk factors and comorbidities. | Cook S et al. | — | 2015 | → |
| Serum Bilirubin and Disease Progression in Mild COPD. | Apperley S et al. | — | 2015 | → |
| Seven-day continuous abstinence rate from smoking at 1, 2, or 3 years after the use of varenicline. | Kim JS et al. | — | 2015 | → |
| Smoking-cessation advice to patients with chronic obstructive pulmonary disease: the critical roles of health insurance and source of care. | Tilert TJ et al. | — | 2015 | → |
| Statement on smoking cessation in COPD and other pulmonary diseases and in smokers with comorbidities who find it difficult to quit. | Jiménez-Ruiz CA et al. | — | 2015 | → |
| Telomerase mutations in smokers with severe emphysema. | Stanley SE et al. | — | 2015 | → |
| The complex association of metabolic syndrome and its components with computed tomography-determined emphysema index. | Park HY et al. | — | 2015 | → |
| The effects of marijuana exposure on expiratory airflow. A study of adults who participated in the U.S. National Health and Nutrition Examination Study. | Kempker JA et al. | — | 2015 | → |
| The formulation of a pressurized metered dose inhaler containing theophylline for inhalation. | Zhu B et al. | — | 2015 | → |
| The relationship between Helicobacter pylori seropositivity and COPD. | Sze MA et al. | — | 2015 | → |
| The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease. | Tashkin DP | — | 2015 | → |
| Treatment patterns of chronic obstructive pulmonary disease in employed adults in the United States. | Diette GB et al. | — | 2015 | → |
| Updates in the management of stable chronic obstructive pulmonary disease. | Narsingam S et al. | — | 2015 | → |
| Value of systematic intervention for chronic obstructive pulmonary disease in a regional Japanese city based on case detection rate and medical cost. | Tawara Y et al. | — | 2015 | → |
| Accuracy of diagnosis and classification of COPD in primary and specialist nurse-led respiratory care in Rotherham, UK: a cross-sectional study. | Strong M et al. | — | 2014 | → |
| A Decade of National Heart, Lung, and Blood Institute Programs Supporting COPD Research and Education . | Postow L et al. | — | 2014 | → |
| An aberrant leukotriene A4 hydrolase-proline-glycine-proline pathway in the pathogenesis of chronic obstructive pulmonary disease. | Wells JM et al. | — | 2014 | → |
| A prospective study on bacterial and atypical etiology of acute exacerbation in chronic obstructive pulmonary disease. | Nakou A et al. | — | 2014 | → |
| Chronic obstructive pulmonary disease: clinical integrative physiology. | O'Donnell DE et al. | — | 2014 | → |
| Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications. | Qureshi H et al. | — | 2014 | → |
| Chronic obstructive pulmonary disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. | Drummond MB et al. | — | 2014 | → |
| Chronic productive cough is associated with death in smokers with early COPD. | Putcha N et al. | — | 2014 | → |
| COPD patients with exertional desaturation are at a higher risk of rapid decline in lung function. | Kim C et al. | — | 2014 | → |
| COPD prognosis in relation to diagnostic criteria for airflow obstruction in smokers. | Akkermans RP et al. | — | 2014 | → |
| Early intervention with tiotropium in Chinese patients with GOLD stages I-II chronic obstructive pulmonary disease (Tie-COPD): study protocol for a multicentre, double-blinded, randomised, controlled trial. | Li X et al. | — | 2014 | → |
| Effective behaviour change techniques in smoking cessation interventions for people with chronic obstructive pulmonary disease: a meta-analysis. | Bartlett YK et al. | — | 2014 | → |
| Effects of two Chinese herbal formulae for the treatment of moderate to severe stable chronic obstructive pulmonary disease: a multicenter, double-blind, randomized controlled trial. | Wang G et al. | — | 2014 | → |
| [French Pulmonary Medicine Society. Guidelines for clinical practice. Management of COPD. Update 2012: Pulmonary function tests. Full length text]. | Perez T et al. | — | 2014 | → |
| Health-related quality of life and chronic obstructive pulmonary disease in early stages - longitudinal results from the population-based KORA cohort in a working age population. | Wacker ME et al. | — | 2014 | → |
| Impact of chronic obstructive pulmonary disease on morbidity and mortality after myocardial infarction. | Andell P et al. | — | 2014 | → |
| Improving early-stage diagnosis and management of COPD in primary care. | Casaburi R et al. | — | 2014 | → |
| Interrelated role of cigarette smoking, oxidative stress, and immune response in COPD and corresponding treatments. | Zuo L et al. | — | 2014 | → |
| Large-scale genome-wide association studies and meta-analyses of longitudinal change in adult lung function. | Tang W et al. | — | 2014 | → |
| Lessons from ECLIPSE: a review of COPD biomarkers. | Faner R et al. | — | 2014 | → |
| Longer telomere length in COPD patients with α1-antitrypsin deficiency independent of lung function. | Saferali A et al. | — | 2014 | → |
| Long-term dynamics of death rates of emphysema, asthma, and pneumonia and improving air quality. | Kravchenko J et al. | — | 2014 | → |
| Natural history of attempts to stop smoking. | Hughes JR et al. | — | 2014 | → |
| New developments in the assessment of COPD: early diagnosis is key. | Csikesz NG et al. | — | 2014 | → |
| Not all smokers die young: a model for hidden heterogeneity within the human population. | Levine M et al. | — | 2014 | → |
| p38 mitogen-activated protein kinase determines the susceptibility to cigarette smoke-induced emphysema in mice. | Marumo S et al. | — | 2014 | → |
| Pneumonia associated with inhaled corticosteroid use in chronic obstructive pulmonary disease: another perspective. | Scanlon PD | — | 2014 | → |
| Prevalence of airflow limitation in outpatients with cardiovascular diseases in Japan. | Onishi K et al. | — | 2014 | → |
| Preventing COPD exacerbations: new options for a crucial and growing problem. | Curtis JL et al. | — | 2014 | → |
| [Screening for chronic obstructive pulmonary disease by electronic mini-spirometry in general practice]. | Vorilhon P et al. | — | 2014 | → |
| Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. | Vestbo J et al. | — | 2014 | → |
| Smoking cessation. | Rennard SI et al. | — | 2014 | → |
| [Smoking cessation in smokers with chronic obstructive pulmonary disease]. | Underner M et al. | — | 2014 | → |
| Stepping down therapy in COPD. | Reilly JJ | — | 2014 | → |
| Targeting occult heart failure in intensive care unit patients with acute chronic obstructive pulmonary disease exacerbation: effect on outcome and quality of life. | Matamis D et al. | — | 2014 | → |
| The Saudi Guidelines for the Diagnosis and Management of COPD. | Khan JH et al. | — | 2014 | → |
| Will expanded ART use reduce the burden of HIV-associated chronic lung disease? | Kunisaki KM | — | 2014 | → |
| Advancing sex and gender competency in medicine: sex & gender women's health collaborative. | McGregor AJ et al. | — | 2013 | → |
| A new approach to classification of disease severity and progression of COPD. | Mannino DM et al. | — | 2013 | → |
| Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD. | Tashkin DP et al. | — | 2013 | → |
| Blood specimen biomarkers of inflammation, matrix degradation, angiogenesis, and cardiac involvement: a future useful tool in assessing clinical outcomes of COPD patients in clinical practice? | Kristan SS | — | 2013 | → |
| Changes in COPD mortality rate after amendments to the Preventive Vaccination Law in Japan. | Kiyohara K et al. | — | 2013 | → |
| Chronic obstructive pulmonary disease. | Vijayan VK | — | 2013 | → |
| Club cell protein 16 and disease progression in chronic obstructive pulmonary disease. | Park HY et al. | — | 2013 | → |
| Comparison of arterial and venous blood biomarker levels in chronic obstructive pulmonary disease. | Kelly E et al. | — | 2013 | → |
| Complex airway disease: an approach to assessment and management. | Pavord ID | — | 2013 | → |
| Early detection of COPD in general practice: implementation, workload and socioeconomic status. A mixed methods observational study. | Dirven JA et al. | — | 2013 | → |
| Effectiveness of spirometry as a motivational tool for smoking cessation: a clinical trial, the ESPIMOAT study. | Irizar-Aramburu MI et al. | — | 2013 | → |
| Focusing a gender lens on emergency medicine research: 2012 update. | McGregor AJ et al. | — | 2013 | → |
| Genome-wide study identifies two loci associated with lung function decline in mild to moderate COPD. | Hansel NN et al. | — | 2013 | → |
| Humans have antibodies against a plant virus: evidence from tobacco mosaic virus. | Liu R et al. | — | 2013 | → |
| Introducing the COPD Foundation Guide for Diagnosis and Management of COPD, recommendations of the COPD Foundation. | Rennard S et al. | — | 2013 | → |
| Mind-body practices: an alternative, drug-free treatment for smoking cessation? A systematic review of the literature. | Carim-Todd L et al. | — | 2013 | → |
| Oral huangqi formulae for stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. | Wu L et al. | — | 2013 | → |
| Pharmacogenetics of chronic obstructive pulmonary disease. | Hizawa N | — | 2013 | → |
| Pulmonary function change in patients with Sauropus androgynus-related obstructive lung disease 15 years later. | Ou CY et al. | — | 2013 | → |
| Rationale for earlier treatment in COPD: a systematic review of published literature in mild-to-moderate COPD. | Maltais F et al. | — | 2013 | → |
| Risk factors and intervention for chronic obstructive pulmonary disease in China. | Zhou Y et al. | — | 2013 | → |
| Safety and tolerability of inhalational anticholinergics in COPD. | Sharafkhaneh A et al. | — | 2013 | → |
| Should mild COPD be treated? Evidence for early pharmacological intervention. | Elbehairy AF et al. | — | 2013 | → |
| Smoking cessation and COPD. | Tønnesen P | — | 2013 | → |
| [Smoking cessation in case of chronic kidney disease]. | Rostoker G et al. | — | 2013 | → |
| Smoking cessation strategies in patients with COPD. | Warnier MJ et al. | — | 2013 | → |
| Supporting smoking cessation in chronic obstructive pulmonary disease with behavioral intervention: a randomized controlled trial. | Lou P et al. | — | 2013 | → |
| The clinical and economic burden of chronic obstructive pulmonary disease in the USA. | Guarascio AJ et al. | — | 2013 | → |
| The effect of reducing the number of cigarettes smoked on risk of lung cancer, COPD, cardiovascular disease and FEV(1)--a review. | Lee PN | — | 2013 | → |
| The importance of components of pulmonary rehabilitation, other than exercise training, in COPD. | Hill K et al. | — | 2013 | → |
| The relation of serum myeloperoxidase to disease progression and mortality in patients with chronic obstructive pulmonary disease (COPD). | Park HY et al. | — | 2013 | → |
| Treatment of smoking in smokers with chronic obstructive pulmonary disease. Sociedad Española de Neumología y Cirugía Torácica (SEPAR). | Jiménez-Ruiz CA et al. | — | 2013 | → |
| Trends in the prevalence of obstructive and restrictive lung function among adults in the United States: findings from the National Health and Nutrition Examination surveys from 1988-1994 to 2007-2010. | Ford ES et al. | — | 2013 | → |
| Acute exacerbations of chronic obstructive pulmonary disease in the emergency department. | Brulotte CA et al. | — | 2012 | → |
| Acute pulmonary admissions following implementation of a national workplace smoking ban. | Kent BD et al. | — | 2012 | → |
| A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. | Cho MH et al. | — | 2012 | → |
| A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease. | Menn P et al. | — | 2012 | → |
| An association between chronic obstructive pulmonary disease and abdominal aortic aneurysm beyond smoking: results from a case-control study. | Meijer CA et al. | — | 2012 | → |
| Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. | Nishimura M et al. | — | 2012 | → |
| A pragmatic cluster randomized controlled trial of early intervention for chronic obstructive pulmonary disease by practice nurse-general practitioner teams: Study Protocol. | Bunker JM et al. | — | 2012 | → |
| A review of smoking cessation interventions for smokers aged 50 and older. | Zbikowski SM et al. | — | 2012 | → |
| Association between marijuana exposure and pulmonary function over 20 years. | Pletcher MJ et al. | — | 2012 | → |
| Association of dopamine-related gene alleles, smoking behavior and decline in FEV1 in subjects with COPD: findings from the lung health study. | Tashkin DP et al. | — | 2012 | → |
| Behavioral medicine approaches to chronic obstructive pulmonary disease. | von Leupoldt A et al. | — | 2012 | → |
| Biomedical risk assessment as an aid for smoking cessation. | Bize R et al. | — | 2012 | → |
| Cause-specific mortality adjudication in the UPLIFT® COPD trial: findings and recommendations. | McGarvey LP et al. | — | 2012 | → |
| Chronic obstructive pulmonary disease. | Decramer M et al. | — | 2012 | → |
| Chronic obstructive pulmonary disease: a modifiable risk factor for cardiovascular disease? | Stone IS et al. | — | 2012 | → |
| [Chronic obstructive pulmonary disease : new pharmacotherapeutic options]. | Greulich T et al. | — | 2012 | → |
| Comparison of the variability of the annual rates of change in FEV₁ determined from serial measurements of the pre- versus post-bronchodilator FEV₁ over 5 years in mild to moderate COPD: results of the lung health study. | Tashkin DP et al. | — | 2012 | → |
| Contribution of the environment and comorbidities to chronic obstructive pulmonary disease phenotypes. | Martinez CH et al. | — | 2012 | → |
| Cost effectiveness of strategies to combat chronic obstructive pulmonary disease and asthma in sub-Saharan Africa and South East Asia: mathematical modelling study. | Stanciole AE et al. | — | 2012 | → |
| Defining patient-reported outcomes in chronic obstructive pulmonary disease: the patient-centered experience. | Singer JP et al. | — | 2012 | → |
| Development of a patient needs assessment model for pulmonary rehabilitation. | Sully JL et al. | — | 2012 | → |
| Four-year trial of tiotropium in chronic obstructive pulmonary disease. | D'Urzo AD et al. | — | 2012 | → |
| Functional characterization of the matrix metalloproteinase-1 cigarette smoke-responsive region and association with the lung health study. | Wallace AM et al. | — | 2012 | → |
| Genetic epidemiology of cigarette smoke-induced lung disease. | Schwartz AG | — | 2012 | → |
| How I would manage a man with COPD who has few symptoms and is at low risk of an exacerbation: a primary care perspective from Australia. | Zwar N | — | 2012 | → |
| Immunological Features of Chronic Obstructive Pulmonary Disease (COPD) Induced by Indoor Pollution and Cigarette Smoke. | Mortaz E et al. | — | 2012 | → |
| Improved prediction of COPD in at-risk patients using lung function pre-screening in primary care: a real-life study and cost-effectiveness analysis. | Thorn J et al. | — | 2012 | → |
| Interpreting lung function data using 80% predicted and fixed thresholds identifies patients at increased risk of mortality. | Mannino DM et al. | — | 2012 | → |
| Is it asthma, COPD, or something in between, and does it matter? | Tashkin DP | — | 2012 | → |
| Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease. | Celli BR et al. | — | 2012 | → |
| Lung function decline in COPD. | Tantucci C et al. | — | 2012 | → |
| Mast cells in COPD airways: relationship to bronchodilator responsiveness and angiogenesis. | Soltani A et al. | — | 2012 | → |
| Modifying the course of chronic obstructive pulmonary disease: looking beyond the FEV1. | Zuwallack RL et al. | — | 2012 | → |
| Muscarinic receptor antagonists: effects on pulmonary function. | Buels KS et al. | — | 2012 | → |
| NFE2L2 pathway polymorphisms and lung function decline in chronic obstructive pulmonary disease. | Sandford AJ et al. | — | 2012 | → |
| Risk factors for COPD spirometrically defined from the lower limit of normal in the BOLD project. | Hooper R et al. | — | 2012 | → |
| Role of parasympathetic nerves and muscarinic receptors in allergy and asthma. | Scott GD et al. | — | 2012 | → |
| Salmeterol improves fluid clearance from alveolar-capillary membrane in COPD patients: a pilot study. | Di Marco F et al. | — | 2012 | → |
| Sex differences and sex steroids in lung health and disease. | Townsend EA et al. | — | 2012 | → |
| Single-nucleotide polymorphisms in the TSPYL-4 and NT5DC1 genes are associated with susceptibility to chronic obstructive pulmonary disease. | Guo Y et al. | — | 2012 | → |
| Smoking cessation for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis. | Thabane M et al. | — | 2012 | → |
| Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease. | Drummond MB et al. | — | 2012 | → |
| [Spirometry as method of screening and intervention in high- risk smokers in primary care]. | Clotet J et al. | — | 2012 | → |
| The effects of cigarette smoke on airway inflammation in asthma and COPD: therapeutic implications. | Tamimi A et al. | — | 2012 | → |
| The influence of informal caregivers on adherence in COPD patients. | Trivedi RB et al. | — | 2012 | → |
| The relationship between lung inflammation and cardiovascular disease. | Van Eeden S et al. | — | 2012 | → |
| The relationship between telomere length and mortality in chronic obstructive pulmonary disease (COPD). | Lee J et al. | — | 2012 | → |
| Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease. | Keating GM | — | 2012 | → |
| To what causes do people attribute their chronic breathlessness? A population survey. | Johnson MJ et al. | — | 2012 | → |
| Undertreatment of COPD: a retrospective analysis of US managed care and Medicare patients. | Make B et al. | — | 2012 | → |
| Unifying thoracic biomarkers: surfactant protein-D and beyond. | Jaw JE et al. | — | 2012 | → |
| Vascular risk in chronic obstructive pulmonary disease: role of inflammation and other mediators. | Man SF et al. | — | 2012 | → |
| Visual versus automated evaluation of chest computed tomography for the presence of chronic obstructive pulmonary disease. | Mets OM et al. | — | 2012 | → |
| Why do smokers diagnosed with COPD not quit smoking? - a qualitative study. | Eklund BM et al. | — | 2012 | → |
| α1,6-Fucosyltransferase (Fut8) is implicated in vulnerability to elastase-induced emphysema in mice and a possible non-invasive predictive marker for disease progression and exacerbations in chronic obstructive pulmonary disease (COPD). | Kamio K et al. | — | 2012 | → |
| A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. | Lock K et al. | — | 2011 | → |
| Adverse health consequences in COPD patients with rapid decline in FEV1--evidence from the UPLIFT trial. | Kesten S et al. | — | 2011 | → |
| A method to study the effect of bronchodilators on smoke retention in COPD patients: study protocol for a randomized controlled trial. | van Dijk WD et al. | — | 2011 | → |
| An interaction between Nrf2 polymorphisms and smoking status affects annual decline in FEV1: a longitudinal retrospective cohort study. | Masuko H et al. | — | 2011 | → |
| Assessment and management of chronic obstructive pulmonary disease in the emergency department and beyond. | Rowe BH et al. | — | 2011 | → |
| Association between SNPs in pre-miRNA and risk of chronic obstructive pulmonary disease. | Li LJ et al. | — | 2011 | → |
| Change in FEV1 over time in COPD. | van Dijk WD et al. | — | 2011 | → |
| Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease. | Donohue JF et al. | — | 2011 | → |
| Circulating surfactant protein-D and the risk of cardiovascular morbidity and mortality. | Hill J et al. | — | 2011 | → |
| Copd. | McIvor RA et al. | — | 2011 | → |
| COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population. | Fletcher MJ et al. | — | 2011 | → |
| Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease. | Hoogendoorn M et al. | — | 2011 | → |
| Diagnosing and treating COPD: understanding the challenges and finding solutions. | Fromer L | — | 2011 | → |
| Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. | Qaseem A et al. | — | 2011 | → |
| Echocardiographic evaluation of heart in chronic obstructive pulmonary disease patient and its co-relation with the severity of disease. | Gupta NK et al. | — | 2011 | → |
| Effectiveness of a structured motivational intervention including smoking cessation advice and spirometry information in the primary care setting: the ESPITAP study. | Martin-Lujan F et al. | — | 2011 | → |
| Effectiveness of regular reporting of spirometric results combined with a smoking cessation advice by a primary care physician on smoking quit rate in adult smokers: a randomized controlled trial. ESPIROTAB study. | Rodriguez-Alvarez M et al. | — | 2011 | → |
| Effect of gene environment interactions on lung function and cardiovascular disease in COPD. | Hackett TL et al. | — | 2011 | → |
| Effect of heme oxygenase-1 polymorphisms on lung function and gene expression. | Tanaka G et al. | — | 2011 | → |
| Effects of inhalation or incubation of oxitropium bromide on diaphragm muscle contractility in mice. | Shindoh C et al. | — | 2011 | → |
| Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. | Tashkin DP et al. | — | 2011 | → |
| Emerging treatment options in the management of non-small cell lung cancer. | Filosso PL et al. | — | 2011 | → |
| FEV(1)/FVC fixed ratio again! | Fabbri LM | — | 2011 | → |
| General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. | Hilberink SR et al. | — | 2011 | → |
| Improved patient outcome with smoking cessation: when is it too late? | Wu J et al. | — | 2011 | → |
| Incidence of airflow limitation among employees in Norwegian smelters. | Søyseth V et al. | — | 2011 | → |
| Is it possible to diagnose the therapeutic adherence of patients with COPD in clinical practice? A cohort study. | Barnestein-Fonseca P et al. | — | 2011 | → |
| Lung cancer: epidemiology, etiology, and prevention. | Dela Cruz CS et al. | — | 2011 | → |
| Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients. | Tashkin DP et al. | — | 2011 | → |
| Maintenance pharmacotherapy of mild and moderate COPD: what is the evidence? | Ferguson GT | — | 2011 | → |
| Management of chronic obstructive pulmonary disease in Australia after the publication of national guidelines. | Ta M et al. | — | 2011 | → |
| Mind-mapping for lung cancer: towards a personalized therapeutics approach. | Mollberg N et al. | — | 2011 | → |
| Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD. | Moulton BC et al. | — | 2011 | → |
| New horizons in early stage COPD--improving knowledge, detection and treatment. | Decramer M et al. | — | 2011 | → |
| Optimizing management of chronic obstructive pulmonary disease in the upcoming decade. | Russell R et al. | — | 2011 | → |
| Patient phenotyping and early disease detection in chronic obstructive pulmonary disease. | Parr DG | — | 2011 | → |
| Pre- and post-bronchodilator lung function as predictors of mortality in the Lung Health Study. | Mannino DM et al. | — | 2011 | → |
| Prevalence of airway obstruction assessed by lung function questionnaire. | Mintz ML et al. | — | 2011 | → |
| Primary care perspective on chronic obstructive pulmonary disease management. | Make B et al. | — | 2011 | → |
| Simulation-based estimates of effectiveness and cost-effectiveness of smoking cessation in patients with chronic obstructive pulmonary disease. | Atsou K et al. | — | 2011 | → |
| Smoking cessation can improve quality of life among COPD patients: validation of the clinical COPD questionnaire into Greek. | Papadopoulos G et al. | — | 2011 | → |
| [Symptoms and natural history of COPD: role of the distal airways]. | Chaouat A et al. | — | 2011 | → |
| The natural history of chronic obstructive pulmonary disease. | Mannino DM | — | 2011 | → |
| The prevalence of undiagnosed chronic obstructive pulmonary disease in a primary care population with respiratory tract infections - a case finding study. | Sandelowsky H et al. | — | 2011 | → |
| The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. | Casanova C et al. | — | 2011 | → |
| The role of pharmacotherapy in mild to moderate chronic obstructive pulmonary disease. | Raghavan N et al. | — | 2011 | → |
| Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. | Duiverman ML et al. | — | 2011 | → |
| Use of spirometry and recording of smoking habits of COPD patients increased in primary health care during national COPD programme. | Vasankari T et al. | — | 2011 | → |
| Validation of smoking cessation self-reported by patients with chronic obstructive pulmonary disease. | Hilberink SR et al. | — | 2011 | → |
| Varenicline for smoking cessation intervention in chronic obstructive pulmonary disease. | Antoniu SA et al. | — | 2011 | → |
| Vitamin D status and longitudinal lung function decline in the Lung Health Study. | Kunisaki KM et al. | — | 2011 | → |
| Analysis of hospitalizations for COPD exacerbation: opportunities for improving care. | Yip NH et al. | — | 2010 | → |
| An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. | Eisner MD et al. | — | 2010 | → |
| Aquaporin 5 polymorphisms and rate of lung function decline in chronic obstructive pulmonary disease. | Hansel NN et al. | — | 2010 | → |
| Association of COPD with carotid wall intima-media thickness in vascular surgery patients. | van Gestel YR et al. | — | 2010 | → |
| A statistical method for excluding non-variable CpG sites in high-throughput DNA methylation profiling. | Meng H et al. | — | 2010 | → |
| Budesonide/formoterol combination in COPD: a US perspective. | Sharafkhaneh A et al. | — | 2010 | → |
| [Budesonide/formoterol in the treatment of COPD]. | Peces-Barba Romero G et al. | — | 2010 | → |
| Chronic obstructive pulmonary disease after myocardial infarction in the community. | Bursi F et al. | — | 2010 | → |
| Chronic obstructive pulmonary disease biomarker(s) for disease activity needed--urgently. | Vestbo J et al. | — | 2010 | → |
| Clinical practice. Outpatient management of severe COPD. | Niewoehner DE | — | 2010 | → |
| Community based integrated intervention for prevention and management of chronic obstructive pulmonary disease (COPD) in Guangdong, China: cluster randomised controlled trial. | Zhou Y et al. | — | 2010 | → |
| COPD patients with higher education are much less likely to adhere to prescribed daily inhaler use. | Enright PL | — | 2010 | → |
| Current treatment options in smoking cessation. | Crain D et al. | — | 2010 | → |
| Documentation of impaired coronary blood flow in chronic obstructive pulmonary disease patients. | Selcuk H et al. | — | 2010 | → |
| Does physical inactivity cause chronic obstructive pulmonary disease? | Hopkinson NS et al. | — | 2010 | → |
| Early detection of COPD combined with individualized counselling for smoking cessation: a two-year prospective study. | Toljamo T et al. | — | 2010 | → |
| Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. | Bateman E et al. | — | 2010 | → |
| Elevation of sputum matrix metalloproteinase-9 persists up to 6 months after smoking cessation: a research study. | Louhelainen N et al. | — | 2010 | → |
| Exposure to volatile organic compounds and loss of pulmonary function in the elderly. | Yoon HI et al. | — | 2010 | → |
| High-resolution mass spectrometry proteomics for the identification of candidate plasma protein biomarkers for chronic obstructive pulmonary disease. | York TP et al. | — | 2010 | → |
| Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease. | Nicholas BL et al. | — | 2010 | → |
| Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial. | Tashkin DP | — | 2010 | → |
| Improving adherence with inhaler therapy in COPD. | Lareau SC et al. | — | 2010 | → |
| Improving the differential diagnosis of chronic obstructive pulmonary disease in primary care. | Price DB et al. | — | 2010 | → |
| Inhaled albuterol/salbutamol and ipratropium bromide and their combination in the treatment of chronic obstructive pulmonary disease. | Gordon J et al. | — | 2010 | → |
| Interaction in COPD experiment (ICE): a hazardous combination of cigarette smoking and bronchodilation in chronic obstructive pulmonary disease. | van Dijk WD et al. | — | 2010 | → |
| [Limitations of current treatment: unmet needs in the treatment of COPD]. | de Lucas Ramos P et al. | — | 2010 | → |
| [Long-term trials assessing pharmacological treatments in COPD: lessons and limitations]. | Marchand E | — | 2010 | → |
| Low respiratory function increases the risk of depressive symptoms in later life in men. | Giltay EJ et al. | — | 2010 | → |
| Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. | Saccone NL et al. | — | 2010 | → |
| Multistudy fine mapping of chromosome 2q identifies XRCC5 as a chronic obstructive pulmonary disease susceptibility gene. | Hersh CP et al. | — | 2010 | → |
| Pathogenesis of inflammation and repair in advanced COPD. | Cornwell WD et al. | — | 2010 | → |
| Pharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities. | Hersh CP | — | 2010 | → |
| Point: should we abandon FEV₁/FVC <0.70 to detect airway obstruction? No. | Celli BR et al. | — | 2010 | → |
| Preselection of patients at risk for COPD by two simple screening questions. | Kögler H et al. | — | 2010 | → |
| Prevalence and predictors of undiagnosed chronic obstructive pulmonary disease in a Norwegian adult general population. | Hvidsten SC et al. | — | 2010 | → |
| Preventing exacerbations in COPD. | — | — | 2010 | → |
| Proteomic biomarkers in plasma that differentiate rapid and slow decline in lung function in adult cigarette smokers with chronic obstructive pulmonary disease (COPD). | Rana GS et al. | — | 2010 | → |
| Serum metalloproteinase leukolysin (MMP-25/MT-6): a potential metabolic marker for atopy-associated inflammation. | Blumenthal MN et al. | — | 2010 | → |
| Short-term change in self-reported COPD symptoms after smoking cessation in an internet sample. | Etter JF | — | 2010 | → |
| Spirometry for detection of undiagnosed chronic obstructive pulmonary disease in primary care. | Canals-Borrajo G et al. | — | 2010 | → |
| Systematic review of the evidence relating FEV1 decline to giving up smoking. | Lee PN et al. | — | 2010 | → |
| The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD. | Yawn BP et al. | — | 2010 | → |
| The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease. | Beeh KM et al. | — | 2010 | → |
| A 4-year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial). | Tashkin D et al. | — | 2009 | → |
| Adam33 polymorphisms are associated with COPD and lung function in long-term tobacco smokers. | Sadeghnejad A et al. | — | 2009 | → |
| Adenosine receptors in COPD and asymptomatic smokers: effects of smoking cessation. | Versluis M et al. | — | 2009 | → |
| Alternative mechanisms for tiotropium. | Bateman ED et al. | — | 2009 | → |
| A novel polymorphism in CDC6 is associated with the decline in lung function of ex-smokers in COPD. | Takabatake N et al. | — | 2009 | → |
| Anticholinergic treatment in airways diseases. | Flynn RA et al. | — | 2009 | → |
| Association between lung function and disability in African-Americans. | Thorpe RJ et al. | — | 2009 | → |
| Biochemical properties, pharmacokinetics and pharmacological response of tiotropium in chronic obstructive pulmonary disease patients. | Price D et al. | — | 2009 | → |
| Biomarkers of lung damage associated with tobacco smoke in induced sputum. | Comandini A et al. | — | 2009 | → |
| Can a normal peak expiratory flow exclude severe chronic obstructive pulmonary disease? | Perez-Padilla R et al. | — | 2009 | → |
| [Cardiovascular comorbidity in COPD]. | Cataluña JJ et al. | — | 2009 | → |
| Clinical pharmacy-led disease and medicine management programme for patients with COPD. | Khdour MR et al. | — | 2009 | → |
| Clinical predictors of the efficacy of a pulmonary rehabilitation programme in patients with COPD. | Vagaggini B et al. | — | 2009 | → |
| Clinical utility of varenicline for smokers with medical and psychiatric comorbidity. | Ebbert JO et al. | — | 2009 | → |
| [Clinical value of forced expiratory volume in 1 s (FEV1) in chronic obstructive pulmonary disease]. | Gillissen A et al. | — | 2009 | → |
| Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. | Barr RG et al. | — | 2009 | → |
| Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD. | Earnshaw SR et al. | — | 2009 | → |
| Database for physiologically based pharmacokinetic (PBPK) modeling: physiological data for healthy and health-impaired elderly. | Thompson CM et al. | — | 2009 | → |
| Defining disease modification in chronic obstructive pulmonary disease. | Halpin DM et al. | — | 2009 | → |
| Differential assessment and management of asthma vs chronic obstructive pulmonary disease. | Yawn BP | — | 2009 | → |
| Effectiveness of a web-based self-help smoking cessation intervention: protocol of a randomised controlled trial. | Kramer JJ et al. | — | 2009 | → |
| Efficacy of confronting smokers with airflow limitation for smoking cessation. | Kotz D et al. | — | 2009 | → |
| Emerging drugs in chronic obstructive pulmonary disease. | Seifart C et al. | — | 2009 | → |
| Ethical analysis of the justifiability of labelling with COPD for smoking cessation. | Kotz D et al. | — | 2009 | → |
| Exacerbation rate, health status and mortality in COPD--a review of potential interventions. | Seemungal TA et al. | — | 2009 | → |
| From large clinical trials to management of COPD in the real world. | Cazzola M | — | 2009 | → |
| Global assessment of the COPD patient: time to look beyond FEV1? | Papaioannou AI et al. | — | 2009 | → |
| Healthcare for obstructive lung disease in an industrial spirometry surveillance program. | Gulati M et al. | — | 2009 | → |
| [Impact of efficacy and mortality studies (TORCH and UPLIFT) in bronchodilator treatment of chronic obstructive pulmonary disease]. | Soler-Cataluña JJ et al. | — | 2009 | → |
| Improved health-related quality of life after lung volume reduction surgery and pulmonary rehabilitation. | Beling J | — | 2009 | → |
| Improving mucociliary clearance in chronic obstructive pulmonary disease. | Bhowmik A et al. | — | 2009 | → |
| Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies. | Miravitlles M et al. | — | 2009 | → |
| Investigating the natural history of lung function: facts, pitfalls, and opportunities. | Kohansal R et al. | — | 2009 | → |
| Is COPD really a cardiovascular disease? | Sin DD | — | 2009 | → |
| Is there a role for antiinflammatory treatment in COPD? | Beeh KM et al. | — | 2009 | → |
| Is your knowledge up-to-date? COPD. | Barrow SY | — | 2009 | → |
| Leptin receptor polymorphisms and lung function decline in COPD. | Hansel NN et al. | — | 2009 | → |
| Low-dose volumetric computed tomography for quantification of emphysema in asymptomatic smokers participating in an early lung cancer detection trial. | Bastarrika G et al. | — | 2009 | → |
| Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. | Punturieri A et al. | — | 2009 | → |
| [Lung cancer and COPD: a common combination]. | Abal Arca J et al. | — | 2009 | → |
| Management of chronic obstructive pulmonary disease: moving beyond the asthma algorithm. | Gordon E et al. | — | 2009 | → |
| Mortality in alpha-1-antitrypsin deficiency in the United Kingdom. | Dawkins P et al. | — | 2009 | → |
| Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. | Celli B et al. | — | 2009 | → |
| Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. | Young RP et al. | — | 2009 | → |
| Prediction of chronic obstructive pulmonary disease (COPD) in asthma patients using electronic medical records. | Himes BE et al. | — | 2009 | → |
| Predictors of hospital admission for chronic obstructive pulmonary disease exacerbations in Canadian emergency departments. | Rowe BH et al. | — | 2009 | → |
| Preoperative use of inhaled tiotropium in lung cancer patients with untreated COPD. | Kobayashi S et al. | — | 2009 | → |
| Present and future costs of COPD in Iceland and Norway: results from the BOLD study. | Nielsen R et al. | — | 2009 | → |
| Prevalence of COPD among symptomatic patients in a primary care setting. | Yawn B et al. | — | 2009 | → |
| Screening for and early detection of chronic obstructive pulmonary disease. | Soriano JB et al. | — | 2009 | → |
| Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. | Higashimoto Y et al. | — | 2009 | → |
| Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. | Soler-Cataluña JJ et al. | — | 2009 | → |
| Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21 century. | Laniado-Laborín R | — | 2009 | → |
| Smoking cessation: How compelling is the evidence? A review. | Tønnesen P | — | 2009 | → |
| Smoking cessation in chronic obstructive pulmonary disease. | Tashkin DP et al. | — | 2009 | → |
| Smoking cessation interventions in COPD: a network meta-analysis of randomised trials. | Strassmann R et al. | — | 2009 | → |
| Systems biology coupled with label-free high-throughput detection as a novel approach for diagnosis of chronic obstructive pulmonary disease. | Richens JL et al. | — | 2009 | → |
| The day-to-day process of stopping or reducing smoking: a prospective study of self-changers. | Peters EN et al. | — | 2009 | → |
| The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations. | Au DH et al. | — | 2009 | → |
| The prevalence of posttraumatic stress disorder in patients undergoing pulmonary rehabilitation and changes in PTSD symptoms following rehabilitation. | Jones RC et al. | — | 2009 | → |
| Therapeutic strategies to optimize the efficacy of nicotine replacement therapies. | Berlin I | — | 2009 | → |
| Tiotropium bromide: an update. | Heredia JL | — | 2009 | → |
| Tiotropium bromide for chronic obstructive pulmonary disease. | Mamary AJ et al. | — | 2009 | → |
| Transforming growth factor-beta receptor-3 is associated with pulmonary emphysema. | Hersh CP et al. | — | 2009 | → |
| Update on smoking cessation therapies. | Glynn DA et al. | — | 2009 | → |
| What mediates the effect of confrontational counselling on smoking cessation in smokers with COPD? | Kotz D et al. | — | 2009 | → |
| A 4-year trial of tiotropium in chronic obstructive pulmonary disease. | Tashkin DP et al. | — | 2008 | → |
| A candidate gene approach identifies the CHRNA5-A3-B4 region as a risk factor for age-dependent nicotine addiction. | Weiss RB et al. | — | 2008 | → |
| Accuracy of diagnostic registers and management of chronic obstructive pulmonary disease: the Devon primary care audit. | Jones RC et al. | — | 2008 | → |
| Ambroxol in the 21st century: pharmacological and clinical update. | Malerba M et al. | — | 2008 | → |
| An algorithm for choosing among smoking cessation treatments. | Hughes J | — | 2008 | → |
| Association of genetic variations in the CSF2 and CSF3 genes with lung function in smoking-induced COPD. | He JQ et al. | — | 2008 | → |
| Cessation in the use of tobacco - pharmacologic and non-pharmacologic routines in patients. | Quist-Paulsen P | — | 2008 | → |
| Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD? | Man SF et al. | — | 2008 | → |
| Copd. | Kerstjens HA et al. | — | 2008 | → |
| COPD and declining FEV1--time to divide and conquer? | Reilly JJ | — | 2008 | → |
| COPD as a lung disease with systemic consequences--clinical impact, mechanisms, and potential for early intervention. | Decramer M et al. | — | 2008 | → |
| COPD as a systemic disease. | Agusti A et al. | — | 2008 | → |
| COPD-related morbidity and mortality after smoking cessation: status of the evidence. | Godtfredsen NS et al. | — | 2008 | → |
| COPD: what is the unmet need? | Calverley PM | — | 2008 | → |
| Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. | Luisetti M et al. | — | 2008 | → |
| Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomised controlled trial. | Wilson JS et al. | — | 2008 | → |
| Effect of COPD treatments on MRP1-mediated transport in bronchial epithelial cells. | van der Deen M et al. | — | 2008 | → |
| Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. | Celli BR et al. | — | 2008 | → |
| External validation of a COPD diagnostic questionnaire. | Kotz D et al. | — | 2008 | → |
| Gender specific differences in the pros and cons of smoking among current smokers in Eastern Kentucky: implications for future smoking cessation interventions. | Hazen DA et al. | — | 2008 | → |
| Guideline-oriented perioperative management of patients with bronchial asthma and chronic obstructive pulmonary disease. | Yamakage M et al. | — | 2008 | → |
| Health care costs among individuals with chronic obstructive pulmonary disease within several large, multi-state employers. | Darkow T et al. | — | 2008 | → |
| High prevalence of emphysema and its association with BMI: a study of smokers with normal spirometry. | Stratelis G et al. | — | 2008 | → |
| Impact of cancers and cardiovascular diseases in chronic obstructive pulmonary disease. | Sin DD et al. | — | 2008 | → |
| Investigation into the cause of death of a 56-year-old man with serious mental illness. | Prochaska JJ et al. | — | 2008 | → |
| It's about time--directing our attention toward modifying the course of COPD. | Cazzola M et al. | — | 2008 | → |
| Knowledge and attitudes of family physicians coming to COPD continuing medical education. | Yawn BP et al. | — | 2008 | → |
| Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety. | Rossi A et al. | — | 2008 | → |
| Longitudinal study of airway dimensions in chronic obstructive pulmonary disease using computed tomography. | Ohara T et al. | — | 2008 | → |
| Long-term mortality follow-up of the ISOLDE participants: causes of death during 13 years after trial completion. | Bale G et al. | — | 2008 | → |
| Morbidity and mortality in relation to smoking among women and men of Chinese ethnicity: the Singapore Chinese Health Study. | Shankar A et al. | — | 2008 | → |
| Multidisciplinary care of the patient with chronic obstructive pulmonary disease. | Kuzma AM et al. | — | 2008 | → |
| Natural history of emphysema. | Minai OA et al. | — | 2008 | → |
| Outcomes for COPD pharmacological trials: from lung function to biomarkers. | Cazzola M et al. | — | 2008 | → |
| Pharmacotherapy for smoking cessation. | Carrozzi L et al. | — | 2008 | → |
| Primary care of the patient with chronic obstructive pulmonary disease-part 1: frontline prevention and early diagnosis. | Radin A et al. | — | 2008 | → |
| Pulmonary function and the risk of functional limitation in chronic obstructive pulmonary disease. | Eisner MD et al. | — | 2008 | → |
| Pulmonary hypertension associated with COPD. | Elwing J et al. | — | 2008 | → |
| Relapse to smoking after 1 year of abstinence: a meta-analysis. | Hughes JR et al. | — | 2008 | → |
| Role of early detection and pharmacotherapy in chronic obstructive pulmonary disease. | Diaz P et al. | — | 2008 | → |
| Smoking and suicide: a brief overview. | Hughes JR | — | 2008 | → |
| Smoking cessation treatment by Dutch respiratory nurses: reported practice, attitudes and perceived effectiveness. | Kotz D et al. | — | 2008 | → |
| Surfactant protein D: a lung specific biomarker in COPD? | Sin DD et al. | — | 2008 | → |
| The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD. | Hanania NA | — | 2008 | → |
| Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. | Moita J et al. | — | 2008 | → |
| [Treatment of chronic obstructive pulmonary disease in 5 Latin American cities: the PLATINO study]. | López Varela MV et al. | — | 2008 | → |
| [Treatment of mild chronic obstructive pulmonary disease]. | Izquierdo Alonso JL et al. | — | 2008 | → |
| Treatment of mild chronic obstructive pulmonary disease. | Chee A et al. | — | 2008 | → |
| Under-diagnosis of chronic obstructive pulmonary disease: a qualitative study in primary care. | Walters JA et al. | — | 2008 | → |
| Update on the management of COPD. | Celli BR | — | 2008 | → |
| What defines abnormal lung function in older adults with chronic obstructive pulmonary disease? | Bhatt NY et al. | — | 2008 | → |
| Acute exacerbations of chronic bronchitis in elderly patients: pathogenesis, diagnosis and management. | Hayes D et al. | — | 2007 | → |
| Airway mucosal inflammation in COPD is similar in smokers and ex-smokers: a pooled analysis. | Gamble E et al. | — | 2007 | → |
| Anti-inflammatory effects of inhaled carbon monoxide in patients with COPD: a pilot study. | Bathoorn E et al. | — | 2007 | → |
| A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. | Soriano JB et al. | — | 2007 | → |
| A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. | Chan CK et al. | — | 2007 | → |
| A retrospective analysis of disability and its related costs among employees with chronic obstructive pulmonary disease. | Darkow T et al. | — | 2007 | → |
| Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. | McGarvey LP et al. | — | 2007 | → |
| Assessment tools for chronic obstructive pulmonary disease: do newer metrics allow for disease modification? | Mahler DA et al. | — | 2007 | → |
| Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. | O'Donnell DE et al. | — | 2007 | → |
| Chronic obstructive pulmonary disease. | Anthonisen NR | — | 2007 | → |
| Chronic obstructive pulmonary disease and premature aging. | Vogelmeier C et al. | — | 2007 | → |
| Chronic obstructive pulmonary disease in the older patient. | Nazir SA et al. | — | 2007 | → |
| COPD and death: what exactly is the relationship? | Rudolf M | — | 2007 | → |
| Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. | Qaseem A et al. | — | 2007 | → |
| Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency. | Carpenter MJ et al. | — | 2007 | → |
| Early detection of COPD: a case finding study in general practice. | Vandevoorde J et al. | — | 2007 | → |
| Effectiveness of biomedical risk assessment as an aid for smoking cessation: a systematic review. | Bize R et al. | — | 2007 | → |
| Effect of occupational exposures on decline of lung function in early chronic obstructive pulmonary disease. | Harber P et al. | — | 2007 | → |
| Effect of tiotropium bromide on the cardiovascular response to exercise in COPD. | Travers J et al. | — | 2007 | → |
| Efficacy of confrontational counselling for smoking cessation in smokers with previously undiagnosed mild to moderate airflow limitation: study protocol of a randomized controlled trial. | Kotz D et al. | — | 2007 | → |
| External validity of randomized controlled trials in COPD. | Travers J et al. | — | 2007 | → |
| Genetic predisposition to accelerated decline of lung function in COPD. | Molfino NA | — | 2007 | → |
| Global burden of COPD: risk factors, prevalence, and future trends. | Mannino DM et al. | — | 2007 | → |
| Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. | Rabe KF et al. | — | 2007 | → |
| Insulin resistance and inflammation - A further systemic complication of COPD. | Bolton CE et al. | — | 2007 | → |
| Is combination therapy with inhaled anticholinergics and beta2-adrenoceptor agonists justified for chronic obstructive pulmonary disease? | Reddy CB et al. | — | 2007 | → |
| Linking parenchymal disease progression to changes in lung mechanical function by percolation. | Bates JH et al. | — | 2007 | → |
| Management of acute exacerbations of chronic obstructive pulmonary disease in the elderly : an appraisal of published evidence. | Kunisaki KM et al. | — | 2007 | → |
| Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline. | Wilt TJ et al. | — | 2007 | → |
| Maximizing smoking cessation in clinical practice: pharmacologic and behavioral interventions. | Nides M et al. | — | 2007 | → |
| Phenotypes of chronic obstructive pulmonary disease. | Friedlander AL et al. | — | 2007 | → |
| Polymorphisms of interleukin-10 and its receptor and lung function in COPD. | He JQ et al. | — | 2007 | → |
| [Prognostic factors in chronic obstructive pulmonary disease]. | Soler Cataluña JJ et al. | — | 2007 | → |
| Progression parameters for emphysema: a clinical investigation. | Stolk J et al. | — | 2007 | → |
| Quality indicators for the care of chronic obstructive pulmonary disease in vulnerable elders. | Kleerup E | — | 2007 | → |
| Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study. | Garcia-Aymerich J et al. | — | 2007 | → |
| Role of tiotropium in the treatment of COPD. | Rice KL et al. | — | 2007 | → |
| Smoking cessation and bronchial epithelial remodelling in COPD: a cross-sectional study. | Lapperre TS et al. | — | 2007 | → |
| Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. | Tønnesen P et al. | — | 2007 | → |
| Smoking cessation interventions in chronic obstructive pulmonary disease and the role of the family: a systematic literature review. | Luker KA et al. | — | 2007 | → |
| Spirometry, rapid FEV1 decline, and lung cancer among asbestos exposed heavy smokers. | Chien JW et al. | — | 2007 | → |
| Systemic consequences of COPD. | Tkác J et al. | — | 2007 | → |
| Systemic inflammation and mortality in chronic obstructive pulmonary disease. | Sin DD et al. | — | 2007 | → |
| The relationship between exercise tolerance and other outcomes in COPD. | Berry MJ | — | 2007 | → |
| Tiotropium and the treatment of chronic obstructive pulmonary disease. | Anthonisen NR | — | 2007 | → |
| Too little, too late--the patients' perspective on education for COPD. | Jones R | — | 2007 | → |
| Transforming growth factor-beta1 polymorphisms, airway responsiveness and lung function decline in smokers. | Ogawa E et al. | — | 2007 | → |
| Tumour necrosis factor and lymphotoxin A polymorphisms and lung function in smokers. | Tanaka G et al. | — | 2007 | → |
| Under-diagnosis of common chronic diseases: prevalence and impact on human health. | Falagas ME et al. | — | 2007 | → |
| Update on the pharmacologic therapy for chronic obstructive pulmonary disease. | Hanania NA et al. | — | 2007 | → |
| What have we learned from large drug treatment trials in COPD? | Calverley PM et al. | — | 2007 | → |
| Advanced emphysema in African-American and white patients: do differences exist? | Chatila WM et al. | — | 2006 | → |
| An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD. | D'Souza AO et al. | — | 2006 | → |
| An oral selective M3 cholinergic receptor antagonist in COPD. | Lu S et al. | — | 2006 | → |
| Anticholinergic agents in asthma and COPD. | Gross NJ | — | 2006 | → |
| A randomized controlled trial to assess the effects of reimbursing the costs of smoking cessation therapy on sustained abstinence. | Kaper J et al. | — | 2006 | → |
| Assessing the costs of chronic obstructive pulmonary disease: the state medicaid perspective. | Marton JP et al. | — | 2006 | → |
| Association of lung function decline with the heme oxygenase-1 gene promoter microsatellite polymorphism in a general population sample. Results from the European Community Respiratory Health Survey (ECRHS), France. | Guénégou A et al. | — | 2006 | → |
| Biomarkers to assess the utility of potential reduced exposure tobacco products. | Hatsukami DK et al. | — | 2006 | → |
| Biomarkers to assess the utility of potential reduced exposure tobacco products. | Hatsukami DK et al. | — | 2006 | → |
| Can early diagnosis and effective management combat the irresistible rise of COPD? | Jones R | — | 2006 | → |
| Changing the burden of COPD mortality. | Mannino DM et al. | — | 2006 | → |
| Characteristics associated with sustained abstinence from smoking among patients with COPD. | Adams SG et al. | — | 2006 | → |
| Characteristics of patients with COPD in three motivational stages related to smoking cessation. | Hilberink SR et al. | — | 2006 | → |
| Chronic cough due to chronic bronchitis: ACCP evidence-based clinical practice guidelines. | Braman SS | — | 2006 | → |
| Chronic obstructive pulmonary disease: current burden and future projections. | Lopez AD et al. | — | 2006 | → |
| Chronic obstructive pulmonary disease: from unjustified nihilism to evidence-based optimism. | Celli BR | — | 2006 | → |
| Chronic obstructive pulmonary disease: the evidence for use of tiotropium. | Burns G et al. | — | 2006 | → |
| Clinical safety of long-acting beta2-agonist and inhaled corticosteroid combination therapy in COPD. | Decramer M et al. | — | 2006 | → |
| Contribution of alpha- and beta-defensins to lung function decline and infection in smokers: an association study. | Wallace AM et al. | — | 2006 | → |
| C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. | Man SF et al. | — | 2006 | → |
| Developing COPD: a 25 year follow up study of the general population. | Løkke A et al. | — | 2006 | → |
| Development of a COPD severity score. | Wu EQ et al. | — | 2006 | → |
| Economic modeling in chronic obstructive pulmonary disease. | Rutten-van Mölken M et al. | — | 2006 | → |
| Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. | Wu P et al. | — | 2006 | → |
| Epithelial mucin stores are increased in the large airways of smokers with airflow obstruction. | Innes AL et al. | — | 2006 | → |
| Estimating the effect of smoking cessation on weight gain: an instrumental variable approach. | Eisenberg D et al. | — | 2006 | → |
| Genotypes in matrix metalloproteinase 9 are a risk factor for COPD. | Tesfaigzi Y et al. | — | 2006 | → |
| Handle with care: targeting neutrophils in chronic obstructive pulmonary disease and severe asthma? | Beeh KM et al. | — | 2006 | → |
| Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis. | Stockley RA et al. | — | 2006 | → |
| Interferon gamma polymorphisms and their interaction with smoking are associated with lung function. | He JQ et al. | — | 2006 | → |
| Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. | Appleton S et al. | — | 2006 | → |
| Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. | Appleton S et al. | — | 2006 | → |
| Misdiagnosis of COPD and asthma in primary care patients 40 years of age and over. | Tinkelman DG et al. | — | 2006 | → |
| Morphological progression of emphysema on thin-section CT: Analysis of longitudinal change in the number and size of low-attenuation clusters. | Matsuoka S et al. | — | 2006 | → |
| Mortality in COPD: Role of comorbidities. | Sin DD et al. | — | 2006 | → |
| Muscarinic receptor signaling in the pathophysiology of asthma and COPD. | Gosens R et al. | — | 2006 | → |
| Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. | Etter JF et al. | — | 2006 | → |
| Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. | Tønnesen P et al. | — | 2006 | → |
| Nurse-conducted smoking cessation in patients with COPD, using nicotine sublingual tablets and behavioral support. | Pbert L | — | 2006 | → |
| Office-based spirometry for early detection of obstructive lung disease. | Wallace LD et al. | — | 2006 | → |
| Outcomes and markers in the assessment of chronic obstructive pulmonary disease. | Jones PW et al. | — | 2006 | → |
| [Pathogenesis of chronic obstructive pulmonary disease]. | Vogelmeier C et al. | — | 2006 | → |
| Patterns and predictors of smoking cessation in an elderly cohort. | Whitson HE et al. | — | 2006 | → |
| Pharmacological treatment of chronic obstructive pulmonary disease. | Montuschi P | — | 2006 | → |
| Pharmacotherapy for mortality reduction in chronic obstructive pulmonary disease. | Sin DD et al. | — | 2006 | → |
| Pooled clinical trial analysis of tiotropium safety. | Kesten S et al. | — | 2006 | → |
| Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. | Loganathan RS et al. | — | 2006 | → |
| Pulmonary function after exposure to the World Trade Center collapse in the New York City Fire Department. | Banauch GI et al. | — | 2006 | → |
| Relation between duration of smoking cessation and bronchial inflammation in COPD. | Lapperre TS et al. | — | 2006 | → |
| Role of N-acetylcysteine in the management of COPD. | Sadowska AM et al. | — | 2006 | → |
| Smokers with airway obstruction are more likely to quit smoking. | Bednarek M et al. | — | 2006 | → |
| Smoking cessation counseling: a practice management perspective. | Pohlig C | — | 2006 | → |
| Smoking rates and smoking cessation among individuals with multiple sclerosis. | Friend KB et al. | — | 2006 | → |
| Spirometry and smoking cessation advice in general practice: a randomised clinical trial. | Buffels J et al. | — | 2006 | → |
| Technical and functional assessment of 10 office spirometers: A multicenter comparative study. | Liistro G et al. | — | 2006 | → |
| The history of COPD. | Petty TL | — | 2006 | → |
| The impact of repeated spirometry and smoking cessation advice on smokers with mild COPD. | Stratelis G et al. | — | 2006 | → |
| The natural history of chronic obstructive pulmonary disease. | Mannino DM et al. | — | 2006 | → |
| The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding. | Tashkin DP | — | 2006 | → |
| The value of forced expiratory volume in 1 second decline in the assessment of chronic obstructive pulmonary disease progression. | Wise RA | — | 2006 | → |
| Tiotropium bromide. | Lipson DA | — | 2006 | → |
| Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. | Barr RG et al. | — | 2006 | → |
| Underdiagnosed chronic obstructive pulmonary disease in England: new country, same story. | Mannino DM | — | 2006 | → |
| Airway and systemic inflammation and decline in lung function in patients with COPD. | Donaldson GC et al. | — | 2005 | → |
| Are COPD and lung cancer two manifestations of the same disease? | Petty TL | — | 2005 | → |
| Assessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004. | Decramer M et al. | — | 2005 | → |
| Baseline pulmonary function and quality of life 9 years later in a middle-aged Chinese population. | Xie G et al. | — | 2005 | → |
| Benefits of and barriers to the widespread use of spirometry. | Petty TL | — | 2005 | → |
| Bupropion and the risk of sudden death: a self-controlled case-series analysis using The Health Improvement Network. | Hubbard R et al. | — | 2005 | → |
| Challenges and opportunities for combination therapy in chronic obstructive pulmonary disease. | Rennard SI et al. | — | 2005 | → |
| Chronic Chlamydia pneumoniae infection is a risk factor for the development of COPD. | Brandén E et al. | — | 2005 | → |
| Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease. | Sin DD et al. | — | 2005 | → |
| Chronic obstructive pulmonary disease outcome measurements: what's important? What's useful? | Gross NJ | — | 2005 | → |
| Clinical efficacy of OM-85 BV in COPD and chronic bronchitis: a systematic review. | Sprenkle MD et al. | — | 2005 | → |
| COPD: current therapeutic interventions and future approaches. | Barnes PJ et al. | — | 2005 | → |
| Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. | James AL et al. | — | 2005 | → |
| Detecting airflow obstruction in smoking cessation trials: a rationale for routine spirometry. | Bohadana A et al. | — | 2005 | → |
| Development of a quantifiable symptom assessment tool for patients with chronic bronchitis: the Chronic Bronchitis Symptoms Assessment Scale. | Au DH et al. | — | 2005 | → |
| Difficulty in demonstrating a risk from drinking pattern in fourteen years of coronary heart disease morbidity and mortality: the Lung Health Study. | Murray RP et al. | — | 2005 | → |
| Direct costs of COPD in the U.S.: an analysis of Medical Expenditure Panel Survey (MEPS) data. | Miller JD et al. | — | 2005 | → |
| [Don't forget tobacco!]. | Lagrue G et al. | — | 2005 | → |
| Effect of bilateral lung volume reduction surgery on FEV1 decline in severe emphysema. | Travaline JM et al. | — | 2005 | → |
| Effect of smoking on FEV decline in a cross-sectional and longitudinal study of a large cohort of Japanese males. | Omori H et al. | — | 2005 | → |
| Evolution of changes in carbon monoxide transfer factor in men with chronic obstructive pulmonary disease. | Osmanliev DP et al. | — | 2005 | → |
| Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a clinical benefit? | Man SF et al. | — | 2005 | → |
| Inhaled tiotropium for stable chronic obstructive pulmonary disease. | Barr RG et al. | — | 2005 | → |
| Is a long-acting inhaled bronchodilator the first agent to use in stable chronic obstructive pulmonary disease? | Tashkin DP | — | 2005 | → |
| Lack of association of human leukocyte antigen-B7 with COPD and rate of decline in lung function. | Kasuga I et al. | — | 2005 | → |
| Medical symptoms associated with tobacco smoking with and without marijuana abuse among crack cocaine-dependent patients. | Patkar AA et al. | — | 2005 | → |
| Minimal clinically important differences in COPD lung function. | Donohue JF | — | 2005 | → |
| Mucociliary clearance in COPD can be increased by both a D2/beta2 and a standard beta2 agonists. | Hasani A et al. | — | 2005 | → |
| New treatment strategies for COPD. Pairing the new with the tried and true. | Cote CG et al. | — | 2005 | → |
| Non-nicotine pharmacotherapies for smoking cessation. | McRobbie H et al. | — | 2005 | → |
| One hundred years of chronic obstructive pulmonary disease. | Fishman AP | — | 2005 | → |
| One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. | Anzueto A et al. | — | 2005 | → |
| Oral corticosteroids for stable chronic obstructive pulmonary disease. | Walters JA et al. | — | 2005 | → |
| Preparing nurses for the global pandemic of chronic obstructive pulmonary disease. | Kara M | — | 2005 | → |
| Relationship between lung function and physical performance in disabled older women. | Simpson CF et al. | — | 2005 | → |
| Research opportunities in the management of acute exacerbations of chronic obstructive pulmonary disease. | Smithline HA et al. | — | 2005 | → |
| Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. | Johnson GJ et al. | — | 2005 | → |
| Role of antimicrobial agents in the management of exacerbations of COPD. | Sharma S et al. | — | 2005 | → |
| Sleep in COPD patients. | Bhullar S et al. | — | 2005 | → |
| Smoking cessation in patients with COPD in daily general practice (SMOCC): six months' results. | Hilberink SR et al. | — | 2005 | → |
| Smoking cessation, lung function, and weight gain: a follow-up study. | Chinn S et al. | — | 2005 | → |
| Smoking kills: experimental proof from the Lung Health Study. | Samet JM | — | 2005 | → |
| Smoking reduction and the rate of decline in FEV(1): results from the Lung Health Study. | Simmons MS et al. | — | 2005 | → |
| Still looking for answers in COPD. | Donohue JF | — | 2005 | → |
| Systemic response to ambient particulate matter: relevance to chronic obstructive pulmonary disease. | van Eeden SF et al. | — | 2005 | → |
| The adoption of tobacco dependence treatment by rehabilitation clinicians. | Friend KB et al. | — | 2005 | → |
| The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. | Anthonisen NR et al. | — | 2005 | → |
| The most cited authors and papers in tobacco control. | Byrne F et al. | — | 2005 | → |
| The prevalence of acute response to bronchodilator in pulmonary lymphangioleiomyomatosis. | Yen KT et al. | — | 2005 | → |
| The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. | Sin DD et al. | — | 2005 | → |
| The role of tiotropium bromide, a long-acting anticholinergic bronchodilator, in the management of COPD. | Saberi F et al. | — | 2005 | → |
| Willingness of pulmonologists to guide COPD patients in smoking cessation. | Bolman C et al. | — | 2005 | → |
| An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. | Grumelli S et al. | — | 2004 | → |
| A smoking-cessation program consisting of extensive counseling, pharmacotherapy, and office spirometry: results of a pilot project in a Veterans Administration Medical Center. | Kennedy DT et al. | — | 2004 | → |
| Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. | Gan WQ et al. | — | 2004 | → |
| Beta-blockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease. | Au DH et al. | — | 2004 | → |
| [Bronchial inflammation in smokers: clarifying terms]. | Lamela López J et al. | — | 2004 | → |
| Budesonide/formoterol: in chronic obstructive pulmonary disease. | Reynolds NA et al. | — | 2004 | → |
| Calorie-related rapid onset of alveolar loss, regeneration, and changes in mouse lung gene expression. | Massaro D et al. | — | 2004 | → |
| Chronic obstructive pulmonary disease: are women more susceptible than men? | Chapman KR | — | 2004 | → |
| [Chronic obstructive pulmonary disease. Evidence based respiratory medicine: 2nd update workshop of the SPLF]. | Chaouat A et al. | — | 2004 | → |
| Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. | Decramer M et al. | — | 2004 | → |
| COPD: can prevention be improved? Proposal for an integrated intervention strategy. | Ghambarian MH et al. | — | 2004 | → |
| Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. | Sin DD et al. | — | 2004 | → |
| Cost-effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease. | Lee TA et al. | — | 2004 | → |
| Early detection of COPD in primary care: screening by invitation of smokers aged 40 to 55 years. | Stratelis G et al. | — | 2004 | → |
| Effects of asbestos and smoking on the levels and rates of change of lung function in a crocidolite exposed cohort in Western Australia. | Alfonso HS et al. | — | 2004 | → |
| Effects of cigarette smoke on the human airway epithelial cell transcriptome. | Spira A et al. | — | 2004 | → |
| Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. | Sin DD et al. | — | 2004 | → |
| Eletrocardiographic monitoring in COPD patients receiving tiotropium. | Morganroth J et al. | — | 2004 | → |
| Factors associated with outcomes of acute exacerbations of chronic obstructive pulmonary disease. | Tan WC | — | 2004 | → |
| Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease. | Dransfield MT et al. | — | 2004 | → |
| General medicine. | Moore AJ et al. | — | 2004 | → |
| Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary updated 2003. | Fabbri L et al. | — | 2004 | → |
| Glutathione S-transferase variants and their interaction with smoking on lung function. | He JQ et al. | — | 2004 | → |
| Harm reduction approaches to reducing tobacco-related mortality. | Hatsukami DK et al. | — | 2004 | → |
| Lessons from the Lung Health Study. | Anthonisen NR | — | 2004 | → |
| Long-acting bronchodilators are the first-choice option for the treatment of stable COPD. | Cazzola M et al. | — | 2004 | → |
| Longitudinal changes in health status using the chronic respiratory disease questionnaire and pulmonary function in patients with stable chronic obstructive pulmonary disease. | Oga T et al. | — | 2004 | → |
| Long-term pharmacologic management of patients with chronic obstructive pulmonary disease. | Briggs DD et al. | — | 2004 | → |
| Loss of bone density with inhaled triamcinolone in Lung Health Study II. | Scanlon PD et al. | — | 2004 | → |
| Low initial KCO predicts rapid FEV1 decline in pulmonary lymphangioleiomyomatosis. | Lazor R et al. | — | 2004 | → |
| Management of chronic obstructive pulmonary disease. | Sutherland ER et al. | — | 2004 | → |
| Management of stable COPD. | van der Valk P et al. | — | 2004 | → |
| Maternal and personal cigarette smoking synergize to increase airflow limitation in adults. | Upton MN et al. | — | 2004 | → |
| [Mode of action of bronchodilators in COPD. Aims of their use and criteria of assessment]. | Roche N | — | 2004 | → |
| Multicomponent individualized smoking cessation intervention for patients with lung disease. | Jonsdottir H et al. | — | 2004 | → |
| New strategies to improve exercise tolerance in chronic obstructive pulmonary disease. | Ambrosino N et al. | — | 2004 | → |
| Outcome measures for COPD treatments: a critical evaluation. | Gross NJ | — | 2004 | → |
| Outpatient treatment of chronic obstructive pulmonary disease: comparisons with asthma. | Sutherland ER | — | 2004 | → |
| Palliative care in the management of chronic obstructive pulmonary disease. | Blackler L et al. | — | 2004 | → |
| Redefining treatment in COPD: new directions in bronchodilator therapy. | Lipson DA | — | 2004 | → |
| Respiratory medicine. | Pinnock H | — | 2004 | → |
| Reversible cigarette smoke extract-induced DNA damage in human lung fibroblasts. | Kim H et al. | — | 2004 | → |
| Review: long acting beta2 agonists and inhaled corticosteroids reduce exacerbations in chronic obstructive pulmonary disease. | Small S | — | 2004 | → |
| Risk of depression and anxiety in employees with chronic bronchitis: the modifying effect of cigarette smoking. | Wagena EJ et al. | — | 2004 | → |
| Sex and gender differences in lung development and their clinical significance. | Boezen HM et al. | — | 2004 | → |
| Sex differences in COPD and lung cancer mortality trends--United States, 1968-1999. | Kazerouni N et al. | — | 2004 | → |
| Skin manifestations of inhaled corticosteroids in COPD patients: results from Lung Health Study II. | Tashkin DP et al. | — | 2004 | → |
| Smoking cessation improves both direct and indirect airway hyperresponsiveness in COPD. | Willemse BW et al. | — | 2004 | → |
| Spirometry and diabetes: implications of reduced lung function. | Kaminsky DA | — | 2004 | → |
| [Spirometry is a good method for detecting and monitoring chronic obstructive pulmonary disease in high-risk smokers in primary health care]. | Clotet J et al. | — | 2004 | → |
| The effectiveness of a CNS-led community-based COPD screening and intervention program. | DeJong SR et al. | — | 2004 | → |
| The effect of a minimal contact smoking cessation programme in out-patients with chronic obstructive pulmonary disease: a pre-post-test study. | Monninkhof E et al. | — | 2004 | → |
| The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systematic review. | Wagena EJ et al. | — | 2004 | → |
| The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. | Willemse BW et al. | — | 2004 | → |
| The place of inhaled corticosteroids in chronic obstructive pulmonary disease. | Selroos O | — | 2004 | → |
| Therapeutic responses in asthma and COPD. Bronchodilators. | Donohue JF | — | 2004 | → |
| Treatment of stable chronic obstructive pulmonary disease. | Rennard SI | — | 2004 | → |
| Age-related trends in mortality from COPD in Lithuania, 1989 to 1998. | Lesauskaite V | — | 2003 | → |
| Airway inflammation in chronic obstructive pulmonary disease: comparisons with asthma. | Sutherland ER et al. | — | 2003 | → |
| American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. | American Thoracic Society et al. | — | 2003 | → |
| Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. | Gamble E et al. | — | 2003 | → |
| Approaches to slowing the progression of COPD. | Altose MD | — | 2003 | → |
| A prospective evaluation of lung volume reduction surgery in 200 consecutive patients. | Yusen RD et al. | — | 2003 | → |
| A review of lung transplant donor acceptability criteria. | Orens JB et al. | — | 2003 | → |
| Association between glycemic state and lung function: the Framingham Heart Study. | Walter RE et al. | — | 2003 | → |
| Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease. | Wagena EJ et al. | — | 2003 | → |
| Chronic cough and phlegm in young adults. | Cerveri I et al. | — | 2003 | → |
| Chronic obstructive pulmonary disease. | Calverley PM et al. | — | 2003 | → |
| Chronic obstructive pulmonary disease . 7: Management of COPD. | MacNee W et al. | — | 2003 | → |
| Chronic obstructive pulmonary disease 8: non-pharmacological management of COPD. | Morgan MD et al. | — | 2003 | → |
| Chronic obstructive pulmonary disease in geriatric critical care. | Heffner JE et al. | — | 2003 | → |
| Contemporary management of chronic obstructive pulmonary disease: clinical applications. | Man SF et al. | — | 2003 | → |
| Contemporary management of chronic obstructive pulmonary disease: scientific review. | Sin DD et al. | — | 2003 | → |
| COPD: treatments benefit patients. | Rennard SI | — | 2003 | → |
| Current practice in pulmonary function testing. | Evans SE et al. | — | 2003 | → |
| Definition, epidemiology, course, and prognosis of COPD. | Petty TL | — | 2003 | → |
| Detecting chronic obstructive pulmonary disease using peak flow rate: cross sectional survey. | Jackson H et al. | — | 2003 | → |
| Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate. | Górecka D et al. | — | 2003 | → |
| Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. | Jones PW et al. | — | 2003 | → |
| Does smoking affect the outcome of patient education and self-management in asthmatics? | Gallefoss F et al. | — | 2003 | → |
| Effects of lung volume reduction surgery for emphysema on oxygen cost of breathing. | Takayama T et al. | — | 2003 | → |
| Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. | Szafranski W et al. | — | 2003 | → |
| Exercise intervention in patients with chronic obstructive pulmonary disease (CE). | Rosenberg H et al. | — | 2003 | → |
| Future treatment strategies for COPD. | Friedman M | — | 2003 | → |
| Inhaled corticosteroids in chronic obstructive pulmonary disease: new trials and old practices. | O'Riordan TG | — | 2003 | → |
| Ipratropium and lung health study. | Lanes S et al. | — | 2003 | → |
| Is there any association between inhaled ipratropium and mortality in patients with COPD and asthma? | Ringbaek T et al. | — | 2003 | → |
| Lack of long-term adverse adrenal effects from inhaled triamcinolone: Lung Health Study II. | Eichenhorn MS et al. | — | 2003 | → |
| Long-acting inhaled beta 2-agonists for stable COPD. | Dougherty JA et al. | — | 2003 | → |
| Long-term outcome of bilateral lung volume reduction in 250 consecutive patients with emphysema. | Ciccone AM et al. | — | 2003 | → |
| Lung cancer risk reduction after smoking cessation: observations from a prospective cohort of women. | Ebbert JO et al. | — | 2003 | → |
| Management of the symptomatic patient. | Doherty DE | — | 2003 | → |
| Medical management of chronic obstructive pulmonary disease. | Sciurba FC | — | 2003 | → |
| Muscarinic acetylcholine receptors and airway diseases. | Coulson FR et al. | — | 2003 | → |
| Outcome measurements in COPD: are we schizophrenic? | Gross NJ | — | 2003 | → |
| Pathogenesis of COPD. | Rennard SI | — | 2003 | → |
| Pattern of medical charges after quitting smoking among those with and without arthritis, allergies, or back pain. | Musich S et al. | — | 2003 | → |
| Polymorphisms in the IL13, IL13RA1, and IL4RA genes and rate of decline in lung function in smokers. | He JQ et al. | — | 2003 | → |
| Predictors of mortality in alpha1-antitrypsin deficiency. | Dawkins PA et al. | — | 2003 | → |
| Prophylactic anti-inflammation inhibits cigarette smoke-induced emphysema in guinea pigs. | Zhang J et al. | — | 2003 | → |
| Response to Ringbaek et al. | Lanes S | — | 2003 | → |
| Safety issues in pharmacotherapy for smoking in patients with cardiovascular disease. | Joseph AM et al. | — | 2003 | → |
| Severe chronic obstructive pulmonary disease. | Yoneda KY et al. | — | 2003 | → |
| Similarities and differences between asthma and chronic obstructive pulmonary disease: treatment and early outcomes. | Buist AS | — | 2003 | → |
| Smoking cessation for chronic obstructive pulmonary disease. | van der Meer RM et al. | — | 2003 | → |
| Sputum cytology for the detection of early lung cancer. | Petty TL | — | 2003 | → |
| The assessment of health status among patients with COPD. | Curtis JR et al. | — | 2003 | → |
| The effect of smoking intervention and an inhaled bronchodilator on airways reactivity in COPD: the Lung Health Study. | Wise RA et al. | — | 2003 | → |
| The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. | Hanania NA et al. | — | 2003 | → |
| The perioperative management of patients with severe emphysema. | Grichnik KP et al. | — | 2003 | → |
| The pulmonary effects of long-term exposure to aerosol pentamidine: a 5-year surveillance study in HIV-infected patients. | Obaji J et al. | — | 2003 | → |
| The role of pharmacotherapy in assisting smoking cessation. | Waring WS | — | 2003 | → |
| Tobacco-related diseases. | Burns DM | — | 2003 | → |
| Treatment of chronic respiratory failure: lung volume reduction surgery versus rehabilitation. | Decramer M | — | 2003 | → |
| Variability of antioxidant-related gene expression in the airway epithelium of cigarette smokers. | Hackett NR et al. | — | 2003 | → |
| Antioxidant gene polymorphisms and susceptibility to a rapid decline in lung function in smokers. | He JQ et al. | — | 2002 | → |
| Benefits and risks of inhaled corticosteroids in chronic obstructive pulmonary disease. | Bonay M et al. | — | 2002 | → |
| Chronic obstructive pulmonary disease in OAUTHC Ile-Ife: a ten-year review of hospital mortality. | Erhabor GE et al. | — | 2002 | → |
| COPD: clinical phenotypes. | Petty TL | — | 2002 | → |
| [COPD: from unjustified nihilism to reasonable optimism]. | Celli B | — | 2002 | → |
| COPD in 2001: a major challenge for medicine, the pharmaceutical industry, and society. | Rennard SI et al. | — | 2002 | → |
| COPD in perspective. | Petty TL | — | 2002 | → |
| Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. | Van Schayck CP et al. | — | 2002 | → |
| Diagnosis of roentgenographically occult lung cancer by sputum cytology. | Petty TL et al. | — | 2002 | → |
| Early detection and management of COPD. What you can do to reduce the impact of this disabling disease. | Doherty DE | — | 2002 | → |
| Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. | van der Valk P et al. | — | 2002 | → |
| Formoterol: a review of its use in chronic obstructive pulmonary disease. | Cheer SM et al. | — | 2002 | → |
| Formoterol therapy for chronic obstructive pulmonary disease: a review of the literature. | Friedman M et al. | — | 2002 | → |
| Gain and subsequent loss of lung function after lung volume reduction surgery in cases of severe emphysema with different morphologic patterns. | Bloch KE et al. | — | 2002 | → |
| Genetic polymorphisms of matrix metalloproteinases: functional importance in the development of chronic obstructive pulmonary disease? | Wallace AM et al. | — | 2002 | → |
| Global initiative for chronic obstructive lung disease. | Gerald LB et al. | — | 2002 | → |
| Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for chronic obstructive pulmonary disease. | Gómez FP et al. | — | 2002 | → |
| Health-related quality of life after lung volume reduction surgery. | Yusen RD et al. | — | 2002 | → |
| Hospitalizations and mortality in the Lung Health Study. | Anthonisen NR et al. | — | 2002 | → |
| Impact of COPD on pulmonary complications and on long-term survival of patients undergoing surgery for NSCLC. | Sekine Y et al. | — | 2002 | → |
| John Hutchinson's mysterious machine revisited. | Petty TL | — | 2002 | → |
| Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. | Vernooy JH et al. | — | 2002 | → |
| New approaches to lung cancer prevention. | McWilliams A et al. | — | 2002 | → |
| New therapeutic drugs in the management of chronic obstructive pulmonary disease. | Rennard SI | — | 2002 | → |
| Overview of causes of COPD. New understanding of pathogenesis and mechanisms can guide future therapy. | Rennard SI | — | 2002 | → |
| Persistence of the effect of the Lung Health Study (LHS) smoking intervention over eleven years. | Murray RP et al. | — | 2002 | → |
| Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease. | Ram FS et al. | — | 2002 | → |
| Relationship between tobacco smoking and medical symptoms among cocaine-, alcohol-, and opiate-dependent patients. | Patkar AA et al. | — | 2002 | → |
| Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. | Godtfredsen NS et al. | — | 2002 | → |
| Smoking and lung function of Lung Health Study participants after 11 years. | Anthonisen NR et al. | — | 2002 | → |
| Smoking cessation. | Karnath B | — | 2002 | → |
| Smoking cessation in pulmonary rehabilitation: goal or prerequisite? | Lacasse Y et al. | — | 2002 | → |
| The correlation of emphysema or airway obstruction with the risk of lung cancer: a matched case-controlled study. | Kishi K et al. | — | 2002 | → |
| The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease. | Mahler DA | — | 2002 | → |
| The effect of postrehabilitation programmes among individuals with chronic obstructive pulmonary disease. | Brooks D et al. | — | 2002 | → |
| The FEV1/FEV6 predicts lung function decline in adult smokers. | Enright RL et al. | — | 2002 | → |
| Tobacco and alcohol use and medical symptoms among cocaine dependent patients. | Patkar AA et al. | — | 2002 | → |
| Airway hyperresponsiveness and COPD mortality. | Vestbo J et al. | — | 2001 | → |
| Airway infection accelerates decline of lung function in chronic obstructive pulmonary disease. | Wedzicha JA | — | 2001 | → |
| Anticholinergic therapy for bronchiectasis. | Lasserson T et al. | — | 2001 | → |
| Anti-Smoking therapies: is harm reduction a viable alternative to smoking cessation? | Zellweger JP | — | 2001 | → |
| Audit of acute admissions of COPD: standards of care and management in the hospital setting. | Roberts CM et al. | — | 2001 | → |
| [Clinical guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease]. | Barberà JA et al. | — | 2001 | → |
| Commentary: quality of spirometry testing. | Petty TL | — | 2001 | → |
| Drug treatment effects on disease progression. | Chan PL et al. | — | 2001 | → |
| Early detection for lung cancer. New tools for casefinding. | Lam S et al. | — | 2001 | → |
| Early detection of COPD in a high-risk population using spirometric screening. | Zieliñski J et al. | — | 2001 | → |
| Early diagnosis of COPD. | Petty TL | — | 2001 | → |
| Early diagnosis of lung cancer. | Petty TL | — | 2001 | → |
| Economic burden of chronic obstructive pulmonary disease. Impact of new treatment options. | Friedman M et al. | — | 2001 | → |
| Effects of cigarette smoke in mice with different levels of alpha(1)-proteinase inhibitor and sensitivity to oxidants. | Cavarra E et al. | — | 2001 | → |
| Epidemiology of chronic obstructive pulmonary disease. | Antó JM et al. | — | 2001 | → |
| Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. | Pauwels RA et al. | — | 2001 | → |
| Human SLPI inactivation after cigarette smoke exposure in a new in vivo model of pulmonary oxidative stress. | Cavarra E et al. | — | 2001 | → |
| Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease. | Jarvis B et al. | — | 2001 | → |
| Inhaled steroids for COPD? | Tattersfield AE et al. | — | 2001 | → |
| In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. | Loppow D et al. | — | 2001 | → |
| Longitudinal changes in physiological, radiological, and health status measurements in alpha(1)-antitrypsin deficiency and factors associated with decline. | Dowson LJ et al. | — | 2001 | → |
| Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. | Kanner RE et al. | — | 2001 | → |
| Management of chronic obstructive pulmonary disease in the twenty-first century. | Frith P et al. | — | 2001 | → |
| Modern treatment of chronic obstructive pulmonary disease. | Calverley PM | — | 2001 | → |
| Obstructive lung diseases: COPD, asthma, and many imitators. | Ryu JH et al. | — | 2001 | → |
| Pharmacoeconomics of COPD and smoking cessation. | Grannis FW | — | 2001 | → |
| Predictors of loss of lung function in the elderly: the Cardiovascular Health Study. | Griffith KA et al. | — | 2001 | → |
| Repeatability of lung density measurements with low-dose computed tomography in subjects with alpha-1-antitrypsin deficiency-associated emphysema. | Stolk J et al. | — | 2001 | → |
| Should inhaled corticosteroids be used in the long term treatment of chronic obstructive pulmonary disease? | Burge S | — | 2001 | → |
| Simple office spirometry. | Petty TL | — | 2001 | → |
| Smoking cessation: effects on symptoms, spirometry and future trends in COPD. | Pride NB | — | 2001 | → |
| Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. | Tashkin D et al. | — | 2001 | → |
| Susceptibility genes for rapid decline of lung function in the lung health study. | Sandford AJ et al. | — | 2001 | → |
| The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS): hypothesis and design. BRONCUS-trial Committee. | Decramer M et al. | — | 2001 | → |
| The health impact of undiagnosed airflow obstruction in a national sample of United States adults. | Coultas DB et al. | — | 2001 | → |
| The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. | Feenstra TL et al. | — | 2001 | → |
| The National Lung Health Education Program. A new healthcare initiative for America. | Petty TL | — | 2001 | → |
| Tiotropium bromide. | Barnes PJ | — | 2001 | → |
| Characteristics of participants who stop smoking and sustain abstinence for 1 and 5 years in the Lung Health Study. | Murray RP et al. | — | 2000 | → |
| Chronic obstructive pulmonary disease. | Barnes PJ | — | 2000 | → |
| Controversies in the use of spirometry for early recognition and diagnosis of chronic obstructive pulmonary disease in cigarette smokers. | Enright PL et al. | — | 2000 | → |
| COPD: early detection and intervention. | Calverley PM | — | 2000 | → |
| COPD: focus on prevention: recommendations of the National Lung Health Education Program. Chronic obstructive pulmonary disease. | Boyle AH et al. | — | 2000 | → |
| Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. | Lung Health Study Research Group et al. | — | 2000 | → |
| Health promotion for older Americans in the 21st century. | Minkler M et al. | — | 2000 | → |
| Inhaled glucocorticoids in chronic obstructive pulmonary disease. | Mapp CE | — | 2000 | → |
| Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease. | Cazzola M et al. | — | 2000 | → |
| Morphologic grading of emphysema is useful in the selection of candidates for unilateral or bilateral reduction pneumoplasty. | Pompeo E et al. | — | 2000 | → |
| Prevalence of airways obstruction in a general population: European Respiratory Society vs American Thoracic Society definition. | Viegi G et al. | — | 2000 | → |
| Raising awareness of COPD in primary care. | Voelkel NF | — | 2000 | → |
| Reality-based medicine. | Chapman KR | — | 2000 | → |
| Scope of the COPD problem in North America: early studies of prevalence and NHANES III data: basis for early identification and intervention. | Petty TL | — | 2000 | → |
| Smoking cessation. | Rennard SI et al. | — | 2000 | → |
| Smoking cessation guidelines for health professionals: an update. Health Education Authority. | West R et al. | — | 2000 | → |
| The chronic obstructive pulmonary disease exacerbation. | Sherk PA et al. | — | 2000 | → |
| The clinical role of long-acting beta2-agonists in COPD. | Kips J | — | 2000 | → |
| Tobacco dependence treatment in patients with heart and lung disease: implications for intervention and review of pharmacological therapy. | Hays JT | — | 2000 | → |
| Unpredictability of deception in compliance with physician-prescribed bronchodilator inhaler use in a clinical trial. | Simmons MS et al. | — | 2000 | → |
| Update on pharmacologic therapy for chronic obstructive pulmonary disease. | Ferguson GT | — | 2000 | → |
| Utilization in COPD: patient characteristics and diagnostic evaluation. | Mapel DW et al. | — | 2000 | → |